Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Immunology/Infectious Diseases
Clinical Trials: HIV Infections
A listing of clinical trials currently looking for volunteers to enroll in HIV Infections studies. Click on the closest city to find more detailed information on a research study in your area.
Alabama
Birmingham : The University of Alabama at Birmingham Alabama Vaccine Research Clinic
A Safety and Immunogenicity Study of a Plasmid DNA Prime and MVA Boost Vaccine in HIV-1 (Human Immunodeficiency Virus-1) Infected Adults on ART
Birmingham : Alabama
A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)
Birmingham : University of Alabama Birmingham NICHD CRS (5096) Updated
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Birmingham : Alabama Therapeutics CRS (5801)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
Birmingham : University of Alabama at Birmingham
Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus
View More »
Birmingham : 1220.19.0045 Boehringer Ingelheim Investigational Site
Phase III Trial of BI 201335 in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)- Human Immunodeficiency Virus (HIV) Coinfected Patients
Birmingham : UAB 1917 Clinic
Pilot Study of Raltegravir/Truvada Versus Efavirenz/Truvada for Adults With Acute IV-1 Infection
Birmingham : University Of Alabama At Birmingham
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Birmingham : Community Care Building
Seroprevalence of HSV-2 in HIV Infected Subjects and the Effect of Daily Valacyclovir in the Reduction of HSV-2 Recurrence and Viral Shedding
Birmingham : University of Alabama at Birmingham (UAB)
Strategic Timing of Antiretroviral Treatment
Hobson City : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Arizona
Phoenix :
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Etravirine Administered in Combination With Other Antiretroviral Agents in Antiretroviral Treatment-Experienced HIV-1 Infected Patients
Phoenix : Pfizer Investigational Site
An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children
Phoenix : Spectrum Medical Group
Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment
Phoenix : Southwest Center for HIV / AIDS
Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus
Phoenix : Phoenix Children's Hospital
Equivalence of Boosted Atazanavir Based Regimens and Currently Effective HAART Regimens
View More »
Phoenix : Spectrum Medical Group
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Phoenix : Spectrum Medical Group
Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
Phoenix : Pueblo Family Physicians
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Phoenix : Spectrum Medical Group
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
California
Bakersfield : California
A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)
Bakersfield : Franco Felizarta, MD
Boosted Lexiva With Lovaza Adjunctive Therapy in Hypertriglyceridemic, HIV-Infected Subjects
Bakersfield : GSK Investigational Site
Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine
Bakersfield : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Bakersfield : GSK Investigational Site
Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and/or Elivitegravir
View More »
Beverly Hills : AHF Research Center
A Controlled Trial to Evaluate the Effects of GanedenBC30 on the Immune System
Beverly Hills : GSK Investigational Site
A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
Beverly Hills :
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Etravirine Administered in Combination With Other Antiretroviral Agents in Antiretroviral Treatment-Experienced HIV-1 Infected Patients
Beverly Hills : California
A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)
Beverly Hills : AHF Research Center
Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment
Beverly Hills : AIDS Healthcare Foundation Research Center
Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus
Beverly Hills : Pacific Oaks Medical Group
Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus
Beverly Hills : Pacific Oak Medical Group
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Beverly Hills : AHF Research Center
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Beverly Hills : AHF Research Center
Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults
Beverly Hills : AIDS Healthcare Foundation
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Beverly Hills : Pacific Oaks Medical Group
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Burbank :
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Etravirine Administered in Combination With Other Antiretroviral Agents in Antiretroviral Treatment-Experienced HIV-1 Infected Patients
Burbank : Providence Clinical Research
Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus
Fountain Valley : GSK Investigational Site
A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
Garden Grove : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Irvine : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
La Jolla : Scripps Clinic
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Long Beach : Miller Children's Hospital Long Beach NICHD CRS (5093) Updated
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Long Beach : Living Hope Clinical Foundation
Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
Long Beach : VA Long Beach Healthcare System Updated
Pilot Study of Raltegravir Lipodystrophy IISP
Long Beach : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Los Angeles : AIDS Research Alliance
A Safety and Immunogenicity Study of a Plasmid DNA Prime and MVA Boost Vaccine in HIV-1 (Human Immunodeficiency Virus-1) Infected Adults on ART
Los Angeles : GSK Investigational Site
A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in the Central Nervous System in HIV-1 Infected ART-naive Subjects
Los Angeles : GSK Investigational Site
A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
Los Angeles : California
A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)
Los Angeles : UCLA-Los Angeles/Brazil AIDS Consortium (LABAC) CR (3601) Updated
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Los Angeles : Childrens Hospital Los Angeles NICHD CRS (5090) Updated
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Los Angeles : USC/Los Angeles County Medical Center NICHD CRS (5048) Updated
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Los Angeles : Pfizer Investigational Site
An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children
Los Angeles : UCLA CARE Center CRS (601)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
Los Angeles : Kaiser Permanente
Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment
Los Angeles : Peter J. Ruane, M.D., Inc.
Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment
Los Angeles : Anthony Mills
Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus
Los Angeles : Oasis Clinic
Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus
Los Angeles : AIDS Research Alliance
Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus
Los Angeles : Peter J Ruane MD Incorporated
Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus
Los Angeles : Kaiser Permanente Los Angeles
Open-Label Pilot Study to Evaluate Switching From a Regimen Consisting of Raltegravir Plus Emtricitabine/Tenofovir DF Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients
Los Angeles : Anthony Mills MD, Inc
Open-Label Pilot Study to Evaluate Switching From a Regimen Consisting of Raltegravir Plus Emtricitabine/Tenofovir DF Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients
Los Angeles : Peter J. Ruane, MD, Inc.
Open-Label Pilot Study to Evaluate Switching From a Regimen Consisting of Raltegravir Plus Emtricitabine/Tenofovir DF Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients
Los Angeles : UCLA Center for AIDS Research and Education
Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients
Los Angeles : Anthony Mills MD Inc
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Los Angeles : Peter J. Ruane, MD, Inc.
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Los Angeles : Peter J Ruane MD Inc.
Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
Los Angeles : Anthony Mills MD Inc
Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
Los Angeles : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Los Angeles : Southern California Permanente Medical Group
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Los Angeles : Anthony Mills, MD Internal Medicine
Safety and Immune Response Assessment Study of Killed-whole HIV-1 Vaccine (SAV001-H) in Chronic HIV-1 Infected Patients
Los Angeles : University of Southern California
Strategic Timing of Antiretroviral Treatment
Los Angeles : VA Greater Los Angeles Healthcare System
Strategic Timing of Antiretroviral Treatment
Los Angeles : UCLA CARE-4-Families (LABAC CRS)
Strategic Timing of Antiretroviral Treatment
Los Angeles : GSK Investigational Site
Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and/or Elivitegravir
Los Angeles : Peter J. Ruane, M.D., Inc.
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Los Angeles : Anthony Mills MD Inc
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Los Angelos : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Newport Beach : Orange Coast Medical Group
Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment
Newport Beach : Orange Coast Medical Group
Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus
Newport Beach : Orange Coast Medical Group
Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients
Oakland : California
A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)
Oakland : East Bay AIDS Center
Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment
Oakland : Alameda County Medical Center
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Oakland : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Orange : Pfizer Investigational Site
An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children
Orange : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Palm Desert : 1220.19.0007 Boehringer Ingelheim Investigational Site
Phase III Trial of BI 201335 in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)- Human Immunodeficiency Virus (HIV) Coinfected Patients
Palm Desert : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Palm Springs : Desert Medical Group Inc.
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Palo Alto : California
A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)
Palo Alto : Stanford CRS (501)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
Palo Alto : Stanford University ACTU
Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus
Palo Alto : Stanford University
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Sacramento : University of California, Davis
Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment
Sacramento : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Sacramento : UCDavis Research Office at CARES
Safety and Efficacy Study of AGS-004 During Analytical Treatment Interruption
San Diego : GSK Investigational Site
A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in the Central Nervous System in HIV-1 Infected ART-naive Subjects
San Diego : GSK Investigational Site
A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
San Diego : Univ of California, San Diego (4601) Updated
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
San Diego : Ucsd, Avrc Crs (701)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
San Diego : La Playa Medical Group and Clinical Research
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
San Diego : La Playa Medical Group and Clinical Research
Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
San Diego : La Playa Medical Group and Clinical Research
Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults
San Diego : Ucsd Antiviral Research Center
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
San Diego : Naval Medical Center San Diego NMCSD
Strategic Timing of Antiretroviral Treatment
San Diego : UCSD Mother-Child-Adolescent Program
Strategic Timing of Antiretroviral Treatment
San Diego : La Playa Medical Group and Clinical Research
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
San Francisco : Ucsf Aids Crs (801)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
San Francisco : Metropolis Medical
Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment
San Francisco : University of California, San Francisco
Effect of Maraviroc on Endothelial Function in HIV-Infected Patients
San Francisco : University of California, San Francisco
Effect of Raltegravir on Endothelial Function in HIV-Infected Patients
San Francisco : Quest Clinical Research
Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus
San Francisco : University of California at San Francisco
Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus
San Francisco : Quest Clinical Research
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
San Francisco : Benchmark Research
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
San Francisco : University of California, San Francisco; San Francisco General Hospital
Investigation of The Effect of Cenicriviroc (CVC) Plus FTC/TDF on Cardiovascular Disease Risk Factors
San Francisco : University of California San Francisco - San Francisco General Hospital
Maraviroc as an Immunomodulatory Drug for Antiretroviral-treated HIV Infected Patients Exhibiting Immunologic Failure
San Francisco : Quest Clinical Research
Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients
San Francisco : Metropolis Medical
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
San Francisco : Metropolis Medical
Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
San Francisco : 1220.19.0031 Boehringer Ingelheim Investigational Site
Phase III Trial of BI 201335 in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)- Human Immunodeficiency Virus (HIV) Coinfected Patients
San Francisco : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
San Francisco : Kaiser Permanente Medical Center
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
San Francisco : San Francisco General Hospital
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
San Francisco : Metropolis Medical
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
San Francisco : University of California, San Francisco
The Role of Inflammation and Aging in HIV-Associated Cardiovascular Risk
San Francisco, : Univiversity of California San Francisco NICHD CRS (5091) Updated
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Stanford : Stanford University
Maraviroc as an Immunomodulatory Drug for Antiretroviral-treated HIV Infected Patients Exhibiting Immunologic Failure
Stanford : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Torrance : Harbor (UCLA) Medical Center NICHD CRS (5045) Updated
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Torrance : Harbor-UCLA Med. Ctr. CRS (603)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
Colorado
Aurora : University of Colorado, Denver NICHD CRS (5052) Updated
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Aurora : University of Colorado Hospital CRS (6101)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
Denver : University of Colorado Health Sciences Center
A Study of the Drug Interactions Between a Hormonal Emergency Contraception and an HIV Medication
Denver : Denver Public Health CRS
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
Denver : National Jewish Health
Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment
View More »
Denver : University of Colorado Denver and Health Sciences Center
Genetic Predictors of Variability in the Drug-Drug Interaction Between Darunavir/Ritonavir and Pravastatin
Denver : Denver Infectious Disease Consultants, PLLC
Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
Denver : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Denver : Denver Public Health
Strategic Timing of Antiretroviral Treatment
Lafayette : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Connecticut
New Haven : GSK Investigational Site
A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
New Haven : Yale University School of Medicine
Pilot Study of a Raltegravir Based NRTI Sparing Regimen
New Haven : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
New Haven : Yale University School of Medicine
Strategic Timing of Antiretroviral Treatment
Norwalk : GSK Investigational Site
A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
View More »
Norwalk : Circle CARE Center, LLC
Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients
Norwalk : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
West Haven : Va Connecticut Healthcare System
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Delaware
Wilmington : Pfizer Investigational Site
An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children
Florida
Aventura : Neuroscience Consultants, Limited Liability Corporation
Pregabalin Trial In HIV Neuropathic Pain
Aventura : South Florida Medical Research
Pregabalin Trial In HIV Neuropathic Pain
Coral Gables : Sanitas Research
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
Daytona Beach : Updated
A Study to Assess the Pharmacokinetics (Blood Levels) of TMC114 (Darunavir) Taken With Ritonavir and/or TMC125 (Etravirine) and TMC278 (Rilpivirine) in HIV-1 Infected Pregnant Women
Daytona Beach : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
View More »
Fort Lauderdale : GSK Investigational Site
A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
Fort Lauderdale : Broward Health
Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment
Fort Lauderdale : Gary J. Richmond.M.D.,P.A.
Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment
Fort Lauderdale : Therafirst Medical Center
Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment
Fort Lauderdale : Therafirst Medical Centers
Comparison of Plasma & SMARTplasma for Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV) Antibody Testing
Fort Lauderdale : GSK Investigational Site
Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine
Fort Lauderdale : Gary Richmond MD, PA, Inc
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Fort Lauderdale : Gary J. Richmond,M.D., P.A.
Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
Fort Lauderdale : 1220.19.0086 Boehringer Ingelheim Investigational Site
Phase III Trial of BI 201335 in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)- Human Immunodeficiency Virus (HIV) Coinfected Patients
Fort Lauderdale : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Fort Lauderdale : Gary J. Richmond,M.D.,P.A.
Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults
Fort Lauderdale : Children's Diagnostic and Treatment Center, Inc.
Strategic Timing of Antiretroviral Treatment
Fort Lauderdale : Gary Richmond, MD
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Fort Laudersale :
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Etravirine Administered in Combination With Other Antiretroviral Agents in Antiretroviral Treatment-Experienced HIV-1 Infected Patients
Fort Myers : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Fort Pierce : GSK Investigational Site
A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
Fort Pierce : Midway Immunology and Research Center
Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment
Fort Pierce : Midway Immunology and Research Center
Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus
Fort Pierce : Midway Immunology and Research Center
Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
Fort Pierce : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Fort Pierce : GSK Investigational Site
Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and/or Elivitegravir
Ft. Lauderdale : South Florida CDC Ft. Lauderdale NICHD CRS (5055) Updated
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Ft. Lauderdale : Gary Richmond
Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus
Ft. Lauderdale : Therafirst Medical Center
Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus
Jacksonville : Florida
A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)
Jacksonville : Univ. of Florida Jacksonville NICHD CRS (5051) Updated
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Jacksonville : Pfizer Investigational Site
An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children
Jacksonville : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Jacksonville : University of Florida Health Services Center
Strategic Timing of Antiretroviral Treatment
Jacksonville : UF CARES/Rainbow Center
Strategic Timing of Antiretroviral Treatment
Jacksonville : University of Florida, Jacksonville
Strategic Timing of Antiretroviral Treatment
Miami : Updated
A Study to Assess the Pharmacokinetics (Blood Levels) of TMC114 (Darunavir) Taken With Ritonavir and/or TMC125 (Etravirine) and TMC278 (Rilpivirine) in HIV-1 Infected Pregnant Women
Miami :
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Etravirine Administered in Combination With Other Antiretroviral Agents in Antiretroviral Treatment-Experienced HIV-1 Infected Patients
Miami : University of Miami Pediatric Perinatal HIV/AIDS CRS (4201) Updated
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Miami : Pfizer Investigational Site
An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children
Miami : Kinder Medical Group
Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus
Miami : University of Miami School of Medicine
Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus
Miami : Care Resource Inc.
Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus
Miami : The Kinder Medical Group
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Miami : The Kinder Medical Group
Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
Miami : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Miami : University Of Miami School Of Medicine
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Miami : University of Miami School of Medicine, AIDS Clinical Research unit
Safety and Immunogenicity of HIVAX in HIV-1 Infected Subjects
Miami : University of Miami Pediatric Immunology
Strategic Timing of Antiretroviral Treatment
Miami : University of Miami
Strategic Timing of Antiretroviral Treatment
Miami : The Kinder Medical Group
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Miami Beach : Wohlfeiler, Piperato & Associates, LLC
Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus
Miami Beach : Wohlfeiler, Piperato and Associates, LLC
Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients
Miami Beach : Wohlfeiler, Piperato and Associates, LLC
Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
Miami Beach : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Miami Beach : Wohlfeiler, Piperato and Associates, LLC
Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults
Orlando : GSK Investigational Site
A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
Orlando : Florida
A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)
Orlando : IDOCF/ValueHealthMD, LLC
Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment
Orlando : Orlando Immunology Center
Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment
Orlando : Orlando Immunology Center
Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus
Orlando : Orlando Immunology Center
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
Orlando : GSK Investigational Site
Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine
Orlando : Orlando Immunology Center
Open-Label Pilot Study to Evaluate Switching From a Regimen Consisting of Raltegravir Plus Emtricitabine/Tenofovir DF Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients
Orlando : Orlando Immunology Center
Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients
Orlando : ValuHealth MD, LLC
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Orlando : Orlando Immunology Center
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Orlando : Idocf/Valuhealthmd, Llc
Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
Orlando : Orlando Immunology Center
Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
Orlando : 1220.19.0044 Boehringer Ingelheim Investigational Site
Phase III Trial of BI 201335 in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)- Human Immunodeficiency Virus (HIV) Coinfected Patients
Orlando : IDOCF/ValuhealthMD, LLC
Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults
Orlando : Orlando Immunology Center
Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults
Orlando : Orlando Immunology Center
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Orlando : Orange County Health Department/Hug Me
Strategic Timing of Antiretroviral Treatment
Orlando : Orlando Immunology Center
Strategic Timing of Antiretroviral Treatment
Orlando : Idocf/Valuhealthmd, Llc
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Orlando : Orlando Immunology Center
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Pensacola : Infectious Diseases Associates of Northwest Florida
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Pensacola : Infectious Diseases Associates NW FL, PA
Strategic Timing of Antiretroviral Treatment
Pensacola : Infectious Diseases Associates of NW FL, P.A.
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Port Saint Lucie : Updated
A Study to Assess the Pharmacokinetics (Blood Levels) of TMC114 (Darunavir) Taken With Ritonavir and/or TMC125 (Etravirine) and TMC278 (Rilpivirine) in HIV-1 Infected Pregnant Women
Safety Harbor : Health Positive
Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus
Safety Harbor : Health Positive
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Safety Harbor : AHF Health Positive - Tampa Bay
Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
Safety Harbor : Barry M. Rodwick, M. D.
Pilot Assessment of Lopinavir/Ritonavir and Maraviroc
Safety Harbor : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
St Petersburg : Pfizer Investigational Site
An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children
St. Petersburg : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Tampa : Tampa General Hospital NICHD CRS (5111) Updated
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Tampa : USF - Tampa NICHD CRS (5018) Updated
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Tampa : Pfizer Investigational Site
An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children
Tampa : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Tampa : Hillsborough County Health Department/University of South Florida
Strategic Timing of Antiretroviral Treatment
Tampa : St. Joseph's Comprehensive Research Institute
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Vero Beach : Treasure Coast Infectious Disease Consultants
Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus
Vero Beach : 1220.19.0004 Boehringer Ingelheim Investigational Site
Phase III Trial of BI 201335 in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)- Human Immunodeficiency Virus (HIV) Coinfected Patients
Vero Beach : Treasure Coast Infectious Disease Consultants
Strategic Timing of Antiretroviral Treatment
West Palm Beach : Updated
A Study to Assess the Pharmacokinetics (Blood Levels) of TMC114 (Darunavir) Taken With Ritonavir and/or TMC125 (Etravirine) and TMC278 (Rilpivirine) in HIV-1 Infected Pregnant Women
West Palm Beach : Florida
A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)
West Palm Beach : Triple O Research Institute, PA
Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus
West Palm Beach : Triple O Medical Services, P.A.
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
Georgia
Atlanta : AIDS Research Consortium of Atlanta
A Safety and Immunogenicity Study of a Plasmid DNA Prime and MVA Boost Vaccine in HIV-1 (Human Immunodeficiency Virus-1) Infected Adults on ART
Atlanta : Georgia
A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)
Atlanta : The Ponce de Leon Center CRS (5802)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
Atlanta : Centers for Disease Control and Prevention
Botswana TDF/FTC Oral HIV Prophylaxis Trial
Atlanta : AIDS Research Consortium of Atlanta, Inc.
Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus
View More »
Atlanta : Aids Research Consortium Of Atlanta
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
Atlanta : Grady Infectious Diseases Program
Kaletra Sex/Gender Pharmacokinetics (PK) Study: A Switch From Twice Daily to Once Daily Lopinavir/Ritonavir
Atlanta : Atlanta ID Group, PC
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Atlanta : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Atlanta : Aids Research Consortium Of Atlanta
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
Atlanta : Atlanta ID Group
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Augusta : GSK Investigational Site
A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
Augusta : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Decatur : Infectious Disease Specialists of Atlanta
Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment
Decatur : Infectious Disease Specialists of Atlanta
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Decatur : Infectious Disease Specialists of Atlanta
Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
Decatur : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Decatur : Infectious Disease Specialists of Atlanta
Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults
Douglasville : American Red Cross
Comparison of Plasma & SMARTplasma for Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV) Antibody Testing
Macon : Mercer University/ Mercer Medicine Clinical Research
Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment
Macon : Mercer University Mercer Medicine
Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults
Marietta : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Riverdale : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Savannah : Chatham County Health Department
Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus
Savannah : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Hawaii
Honolulu : Hawaii Center for AIDS
Maraviroc Intensification and Peripheral Blood Monocyte HIV DNA Levels
Illinois
Birmingham : Cooper Green Mercy Hospital (CGMH)
Strategic Timing of Antiretroviral Treatment
Chicago : The Ruth M. Rothstein CORE Center
A Comparison of Virco®TYPE HIV-1 Testing Versus Expert Interpretation of Genotypic Results for Control of HIV-1 Replication
Chicago : Illinois
A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)
Chicago : Chicago Children's CRS (4001) Updated
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Chicago : Rush University Cook County Hospital NICHD CRS (5083) Updated
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
View More »
Chicago : Rush Univ. Med. Ctr. ACTG CRS (2702)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
Chicago : Northwestern University CRS (2701)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
Chicago : Northstar Medical Center
Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment
Chicago : Rush University Medical Center
Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-Based HAART in Advanced HIV Disease
Chicago : Howard Brown Health Center
Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-Based HAART in Advanced HIV Disease
Chicago : University of Chicago Hospital
Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-Based HAART in Advanced HIV Disease
Chicago : University of Illinois Medical Center
Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-Based HAART in Advanced HIV Disease
Chicago : Rush University - Stroger Hospital of Cook County
Maraviroc as an Immunomodulatory Drug for Antiretroviral-treated HIV Infected Patients Exhibiting Immunologic Failure
Chicago : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Chicago : University of Illinois at Chicago
Strategic Timing of Antiretroviral Treatment
Chicago : Children's Memorial Hospital
Strategic Timing of Antiretroviral Treatment
Chicago : Ruth M Rothstein CORE Center
Study of Bone Disease in Older HIV-infected Adults
Chicago : John H. Stroger, Jr. Hospital of Cook County/Ruth M. Rothstein CORE Center
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Chicago : Northwestern University Division of Infectious Diseases
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Peoria : Call for Information (Investigational Site 9001)
Isentress Re-examination Study (MK-0518-115 AM1)
Springfield : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Indiana
Indianapolis : Indiana University Infectious Diseases
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
Iowa
Iowa City : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Kentucky
Lexington : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Louisiana
Lafayette : GSK Investigational Site
A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
New Orleans : Tulane University NICHD CRS (5095) Updated
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
New Orleans : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
New Orleans : Tulane University Medical Center
Strategic Timing of Antiretroviral Treatment
Maryland
Baltimore : University of Maryland NICHD CRS (5094) Updated
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Baltimore : Johns Hopkins University NICHD CRS (5092) Updated
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Baltimore : IHV Baltimore Treatment CRS (4651)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
Baltimore : University of Maryland, School of Medicine
Comparison of Plasma & SMARTplasma for Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV) Antibody Testing
Baltimore : Evelyn Jordan Center
Comparison of Plasma & SMARTplasma for Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV) Antibody Testing
View More »
Baltimore : University of Maryland, Institute of Human Virology
R5 Integrase Study in HIV-1 Naive Patients
Bethesda : National Institutes of Health Clinical Center
Strategic Timing of Antiretroviral Treatment
Bethesda : WRNMMC (formerly NNMC)
Strategic Timing of Antiretroviral Treatment
Lutherville : Maryland
A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)
Lutherville : 1220.19.0079 Boehringer Ingelheim Investigational Site
Phase III Trial of BI 201335 in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)- Human Immunodeficiency Virus (HIV) Coinfected Patients
Lutherville : Johns Hopkins University
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Silver Spring : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Massachusetts
Boston : GSK Investigational Site
A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
Boston : Boston Medical Center Ped. HIV Program NICHD CRS (5011) Updated
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Boston : Beth Israel Deaconess Med. Ctr., ACTG CRS (103)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
Boston : Brigham and Women's Hosp. ACTG CRS (107)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
Boston : Massachusetts General Hospital ACTG CRS (101)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
View More »
Boston : Community Research Initiative of New England
Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus
Boston : Community Research Initiative of New England
Open-Label Pilot Study to Evaluate Switching From a Regimen Consisting of Raltegravir Plus Emtricitabine/Tenofovir DF Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients
Boston : Community Research Initiative of New England
Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
Boston : Boston Medical Center Section of Pediatric ID
Strategic Timing of Antiretroviral Treatment
Boston : Children's Hospital, Boston
Strategic Timing of Antiretroviral Treatment
Boston : Community Research Initiative of New England
Strategic Timing of Antiretroviral Treatment
Boston : Boston Medical Center
Strategic Timing of Antiretroviral Treatment
Boston : Massachusetts General Hospital
Subclinical Atherosclerosis in HIV-infected Patients
Framingham : 1220.19.0027 Boehringer Ingelheim Investigational Site
Phase III Trial of BI 201335 in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)- Human Immunodeficiency Virus (HIV) Coinfected Patients
Springfield :
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Etravirine Administered in Combination With Other Antiretroviral Agents in Antiretroviral Treatment-Experienced HIV-1 Infected Patients
Springfield : The Research Institute
Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment
Springfield : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Springfield : Baystate Infectious Diseases Clinical Research
Strategic Timing of Antiretroviral Treatment
Worcester : WNE Maternal Pediatric Adolescent AIDS CRS (7301) Updated
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Michigan
Ann Arbor : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Berkley : Be Well Medical Center
Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment
Berkley : Be Well Medical Center
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Berkley : Be Well Medical Center
Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
Berkley : Be Well Medical Center
Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults
View More »
Berkley : Be Well Medical Center
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Detroit : Wayne State University/Children's Hospital of Michigan NICHD CRS (5041) Updated
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Detroit : Henry Ford Hosp. CRS (31472)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
Detroit : Henry Ford Health System
Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus
Detroit : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Detroit : Henry Ford Health System
Strategic Timing of Antiretroviral Treatment
Detroit : Wayne State University CRS
Strategic Timing of Antiretroviral Treatment
East Lansing : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Grosse Pointe Woods : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Lansing : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Southfield : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
St. Louis : Central West Clinical Research Inc
Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
Minnesota
Minneapolis : Minnesota
A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)
Minneapolis : HIV Program Hennepin County Medical Center
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Minneapolis : Clinic 42 And International Travel Clinic
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
Minneapolis : Minneapolis Medical Research Foundation, Hennepin County Medical Center
Strategic Timing of Antiretroviral Treatment
Minneapolis : Hennepin County Medical Center
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
View More »
Rochester : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Rochester : Mayo Clinic
Strategic Timing of Antiretroviral Treatment
Mississippi
Jackson : GSK Investigational Site
A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
Missouri
Kansas City : GSK Investigational Site
Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects
Kansas City : The Kansas City Free Health Clinic
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Kansas City : The Kansas City Free Health Clinic
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Saint Louis :
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Etravirine Administered in Combination With Other Antiretroviral Agents in Antiretroviral Treatment-Experienced HIV-1 Infected Patients
St. Louis : Washington U CRS (2101)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
View More »
St. Louis : Washington University School of Medicine
Heart Function in HIV-Negative Children Exposed to HIV and HAART
St. Louis : Central West Clinical Research Inc
Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults
St.Louis : Central West Clinical Research, Inc.
Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment
New Jersey
Camden : Cooper Univ. Hosp. CRS (31476)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
Camden : 1220.19.0008 Boehringer Ingelheim Investigational Site
Phase III Trial of BI 201335 in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)- Human Immunodeficiency Virus (HIV) Coinfected Patients
Camden : Cooper University Hospital
Strategic Timing of Antiretroviral Treatment
Hillsborough : ID Care
Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment
Hillsborough : ID Care
Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus
View More »
Hillsborough : 1220.19.0009 Boehringer Ingelheim Investigational Site
Phase III Trial of BI 201335 in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)- Human Immunodeficiency Virus (HIV) Coinfected Patients
Long Branch : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Morristown : Morristown Memorial Hospital
RHIV A Pilot Study Refractory or Intolerant to Highly Active Antiretroviral Therapy (HAART)
Neptune : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Newark : GSK Investigational Site
A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
Newark : New Jersey
A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)
Newark : New Jersey Medical School CRS (2802) Updated
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Newark : New Jersey Medical School-Adult Clinical Research Ctr. CRS (31477)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
Newark : 1220.19.0015 Boehringer Ingelheim Investigational Site
Phase III Trial of BI 201335 in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)- Human Immunodeficiency Virus (HIV) Coinfected Patients
Newark : New Jersey Medical School Adult Clinical Research Center
Strategic Timing of Antiretroviral Treatment
Somers Point : South Jersey Infectious Disease
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Somers Point : South Jersey Infectious Disease
Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
Somers Point : South Jersey Infectious Disease
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
New Mexico
Santa Fe : Southwest CARE Center
Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients
New York
New York : The Rockefeller University Hospital
A Phase 2b Randomized, Double-Blind, Double-Dummy Trial of 100 or 200 mg Once-Daily Doses of Cenicriviroc (CVC, TBR-652) or Once-Daily EFV, Each With Open-Label FTC/TDF, in HIV-1-Infected, Antiretroviral Treatment-Naïve, Adult Patients With Only CCR5-Tropic Virus
View More »
Albany : GSK Investigational Site
A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
Albany : 1220.19.0011 Boehringer Ingelheim Investigational Site
Phase III Trial of BI 201335 in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)- Human Immunodeficiency Virus (HIV) Coinfected Patients
Bronx : GSK Investigational Site
A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
Bronx : Updated
A Study to Assess the Pharmacokinetics (Blood Levels) of TMC114 (Darunavir) Taken With Ritonavir and/or TMC125 (Etravirine) and TMC278 (Rilpivirine) in HIV-1 Infected Pregnant Women
Bronx : New York
A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)
Bronx : Jacobi Med. Ctr. Bronx NICHD CRS (5013) Updated
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Bronx : Bronx-Lebanon Hospital IMPAACT CRS (6901) Updated
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Bronx : Jacobi & North Central Bronx Hospitals
Safety and Efficacy Study of AGS-004 During Analytical Treatment Interruption
Bronx : James J Peters Vamc
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Bronx : Jacobi Medical Center
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
Bronx : Bronx-Lebanon Hospital Center
Strategic Timing of Antiretroviral Treatment
Bronx : Montefiore Medical Center
Strategic Timing of Antiretroviral Treatment
Brooklyn : Synergy First Medical PLLC
Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus
Buffalo : GSK Investigational Site
A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
Buffalo : Erie County Medical Center Corporation
Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus
Buffalo : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Ithaca : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Manhasset : North Shore University Hospital
Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment
Manhasset : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Manhasset : North Shore-Long Island Jewish Health System
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Monticello : Upper Delaware Valley Infectious Diseases, Pc
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Mt. Vernon : Greiger Clinic
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Mt. Vernon : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Mt. Vernon : Greiger Clinic
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
New York : GSK Investigational Site
A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
New York : New York
A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)
New York : New York University NY NICHD CRS (5012) Updated
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
New York : Columbia IMPAACT CRS (4101) Updated
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
New York : Metropolitan Hospital NICHD CRS (5003) Updated
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
New York : Cornell CRS (7804)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
New York : NY Univ. HIV/AIDS CRS (401)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
New York : Mount Sinai Downtown Comprehensive Health Program
Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment
New York : Chelsea Village Medical
Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment
New York : Bellevue Hospital
Comparison of Plasma & SMARTplasma for Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV) Antibody Testing
New York : ACRIA
Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus
New York : Bisher Akil, M.D., A Medical Corporation
Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus
New York : Aaron Diamond AIDS Research Center
Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus
New York : Aids Com. Res. Init. Of Amer
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
New York : Ricky K Hsu, MD, PC
Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients
New York : Aaron Diamond AIDS Research Center
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
New York : 1220.19.0017 Boehringer Ingelheim Investigational Site
Phase III Trial of BI 201335 in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)- Human Immunodeficiency Virus (HIV) Coinfected Patients
New York : 1220.19.0006 Boehringer Ingelheim Investigational Site
Phase III Trial of BI 201335 in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)- Human Immunodeficiency Virus (HIV) Coinfected Patients
New York : 1220.19.0014 Boehringer Ingelheim Investigational Site
Phase III Trial of BI 201335 in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)- Human Immunodeficiency Virus (HIV) Coinfected Patients
New York : 1220.19.0084 Boehringer Ingelheim Investigational Site
Phase III Trial of BI 201335 in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)- Human Immunodeficiency Virus (HIV) Coinfected Patients
New York : Mount Sinai School of Medicine
Pregabalin Trial In HIV Neuropathic Pain
New York : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
New York : Mount Sinai School Of Medicine
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
New York : Chelsea Village Medical
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
New York : Cornell University
Strategic Timing of Antiretroviral Treatment
New York : Harlem Family Center/Columbia University
Strategic Timing of Antiretroviral Treatment
New York : GSK Investigational Site
Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and/or Elivitegravir
New York City : Jacobi Medical Center
Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus
Rochester : Univ. of Rochester ACTG CRS (1101)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
Rochester : AIDS Care CRS (1108)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
Rochester : AIDS Care
Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment
Rochester : University of Rochester
Comparing Raltegravir Genital Tract Distribution in HIV-Infected Men and Women
Rochester : AIDS Care
Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus
Rochester : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Stony Brook : SUNY Stony Brook NICHD CRS (5040) Updated
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Stony Brook : SUNY Stony Brook
Strategic Timing of Antiretroviral Treatment
Syracuse : Suny Upstate Medical University
Phase IIIB Pediatric ATV Powder for Oral Use (POU) (PRINCE2)
Valhalla : GSK Investigational Site
A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
Valhalla : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
North Carolina
Chapel Hill : GSK Investigational Site
A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
Chapel Hill : Updated
A Study to Assess the Pharmacokinetics (Blood Levels) of TMC114 (Darunavir) Taken With Ritonavir and/or TMC125 (Etravirine) and TMC278 (Rilpivirine) in HIV-1 Infected Pregnant Women
Chapel Hill : Unc Aids Crs (3201)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
Chapel Hill : University of North Carolina at Chapel Hill
Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus
Chapel Hill : The University of North Carolina at Chapel Hill
Evaluating Once Daily Etravirine in Treatment-Naive Adults With HIV Infection
View More »
Chapel Hill : The University of North Carolina - Chapel Hill
Pilot Study to Evaluate HIV Viremia and Persistence in Acutely HIV-Infected ARV Naïve Patients Treated With Darunavir/Ritonavir and Etravirine
Chapel Hill : AIDS Clinical Trials Unit
Safety and Efficacy Study of AGS-004 During Analytical Treatment Interruption
Chapel Hill : UNC AIDS Clinical Trials Unit
Strategic Timing of Antiretroviral Treatment
Chapel Hill : Wake County Human Services
Strategic Timing of Antiretroviral Treatment
Chapel Hill : The University of North Carolina at Chapel Hill
The Effect of Vorinostat on HIV RNA Expression in the Resting CD4+ T Cells of HIV+ Pts on Stable ART
Chapel Hill : The University of North Carolina - Chapel Hill
Treatment of Acute HIV With Emtricitabine, Tenofovir and Efavirenz (CID 0805)
Charlotte : Carolinas Medical Center
Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment
Charlotte : Carolinas Medical Center
Evaluating Once Daily Etravirine in Treatment-Naive Adults With HIV Infection
Charlotte : ID Consultants, P.A.
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Charlotte : Carolinas Medical Center
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Charlotte : Id Consultants, Pa
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
Charlotte : ID Consultants, P.A.
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Durham : GSK Investigational Site
A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
Durham : North Carolina
A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)
Durham : Duke University Medical Center (DUMC) Pediatric CRS (4701) Updated
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Durham : Duke Univ. Med. Ctr. Adult CRS (1601)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
Durham : Duke University Medical Center
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
Durham : Duke University
Pilot Study to Evaluate HIV Viremia and Persistence in Acutely HIV-Infected ARV Naïve Patients Treated With Darunavir/Ritonavir and Etravirine
Durham : Duke University Medical Center
Safety and Efficacy Study of AGS-004 During Analytical Treatment Interruption
Durham : Duke Pediatric
Strategic Timing of Antiretroviral Treatment
Durham : Duke University
Strategic Timing of Antiretroviral Treatment
Durham : Duke University
Treatment of Acute HIV With Emtricitabine, Tenofovir and Efavirenz (CID 0805)
Greensboro : Moses H. Cone Memorial Hospital CRS (3203)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
Greensboro : Regional Center for Infectious Disease
Strategic Timing of Antiretroviral Treatment
Greenville : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Huntersville : Rosedale Infectious Disease
Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus
Huntersville : Rosedale Infectious Diseases
Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
Wilmington : Registry Coordinating Center
Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any Major Teratogenic Effect Involving Any of the Registry Drugs When Administered to Pregnant Women.
Wilmington : GSK Investigational Site
Antiretroviral Pregnancy Registry (APR)-Risk of Birth Defects
Winston-Salem : Wake Forest University Health Sciences
Evaluating Once Daily Etravirine in Treatment-Naive Adults With HIV Infection
Winston-Salem : 1220.19.0021 Boehringer Ingelheim Investigational Site
Phase III Trial of BI 201335 in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)- Human Immunodeficiency Virus (HIV) Coinfected Patients
Winston-Salem : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Winston-Salem : Wake Forest University Health Sciences
Strategic Timing of Antiretroviral Treatment
Winston-Salem : Wake Forest University Health Sciences
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Ohio
Akron :
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Etravirine Administered in Combination With Other Antiretroviral Agents in Antiretroviral Treatment-Experienced HIV-1 Infected Patients
Cincinnati : Ohio
A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)
Cincinnati : Univ. of Cincinnati CRS (2401)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
Cincinnati : University of Cincinnati
Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus
Cincinnati : University Of Cincinnati College Of Medicine
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
View More »
Cincinnati : 1220.19.0010 Boehringer Ingelheim Investigational Site
Phase III Trial of BI 201335 in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)- Human Immunodeficiency Virus (HIV) Coinfected Patients
Cincinnati : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Cleveland : Case CRS (2501)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
Cleveland : Metro Health CRS (2503)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
Cleveland : Case Western Reserve University
Maraviroc as an Immunomodulatory Drug for Antiretroviral-treated HIV Infected Patients Exhibiting Immunologic Failure
Cleveland : University Hospitals of Cleveland Case Medical Center
Use of Rosuvastatin in HIV-Infected Subjects to Modulate Cardiovascular Risks
Columbus : The Ohio State Univ. AIDS CRS (2301)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
Columbus : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Columbus : The Ohio State University Medical Center
Strategic Timing of Antiretroviral Treatment
Toledo : GSK Investigational Site
A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
Toledo : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Oklahoma
Oklahoma City : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Oregon
Portland : GSK Investigational Site
A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
Portland : The Research and Education Group - Portland
Strategic Timing of Antiretroviral Treatment
Pennsylvania
Allentown : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Philadelphia : Philadelphia FIGHTS
A Randomized, Dose-Ranging Study of Alferon LDO in Asymptomatic HIV+ Subjects
Philadelphia : Drexel University School of Medicine
A Randomized, Dose-Ranging Study of Alferon LDO in Asymptomatic HIV+ Subjects
Philadelphia : Drexel University College of Medicine
A Study of HIV-infected Subjects Initiating Anti-HIV Drugs for the First Time
Philadelphia : GSK Investigational Site
A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
View More »
Philadelphia : Pennsylvania
A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)
Philadelphia : Drexel University College of Medicine
A Trial of Observed Long-acting, Anti-HIV Treatment With a Monoclonal CCR5 Antibody (PRO 140) as an Adjunct to a New, Optimized, Oral Antiretroviral Regimen in HIV-infected Injection Drug Users With Viral Rebound and Documented Poor Adherence
Philadelphia : Reproductive Research Unit, U of Penn Medical Center
An Imaging Trial of the Distribution of Topical Gel in the Human Vagina: Assessment of Bare Spots
Philadelphia : Pfizer Investigational Site
An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children
Philadelphia : Hosp. of the Univ. of Pennsylvania CRS (6201)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
Philadelphia : University Of Pennsylvania
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
Philadelphia : Temple General Internal Medicine
Kaletra and Maraviroc in Antiretroviral Therapy (ART)-Naive Patients (KALMAR Study)
Philadelphia : GSK Investigational Site
Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine
Philadelphia : 1220.19.0013 Boehringer Ingelheim Investigational Site
Phase III Trial of BI 201335 in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)- Human Immunodeficiency Virus (HIV) Coinfected Patients
Philadelphia : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Philadelphia : Division of Infectious Disease and HIV Medicine Partnership Comprehensive Care Practice
Safety and Efficacy Study of AGS-004 During Analytical Treatment Interruption
Philadelphia : Temple University
Strategic Timing of Antiretroviral Treatment
Philadelphia : Philadelphia FIGHT
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Philadelphia : University of Pennsylvania
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Pittsburgh : Pitt CRS (1001)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
Rhode Island
Providence : The Miriam Hospital
A Study of the Drug Interactions Between a Hormonal Emergency Contraception and an HIV Medication
Providence : GSK Investigational Site
A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
South Carolina
Charleston : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Columbia : South Carlonia
A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)
Columbia : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Tennessee
Texas
Addison : Southwest Infectious Disease Clinical Research, Inc.
Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment
Addison : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Arlington : Texas Clinical Research Institute
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Austin : GSK Investigational Site
A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
Austin : Central Texas Clinical Research
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
View More »
Austin : Central Texas Clinical Research
Open-Label Pilot Study to Evaluate Switching From a Regimen Consisting of Raltegravir Plus Emtricitabine/Tenofovir DF Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients
Austin : Central Texas Clinical Research
Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
Austin : 1220.19.0029 Boehringer Ingelheim Investigational Site
Phase III Trial of BI 201335 in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)- Human Immunodeficiency Virus (HIV) Coinfected Patients
Austin : Central Texas Clinical Research
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
Bellaire : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Bellaire : St. Hope Foundation
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
Dallas : GSK Investigational Site
A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
Dallas : North Texas Infectious Diesease Consultants
Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus
Dallas : UT Southwestern Medical Center at Dallas
HIV Acquired Lipodystrophy (HAL) Classification, Measurement and Fat Response to Thiazolidinedione (TZD) (Pioglitazone)
Dallas : GSK Investigational Site
Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine
Dallas : Southwest Infectious Disease Clinical Researach Inc
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Dallas : Southwest Infectious Disease Clinical Research, Inc.
Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
Dallas : Trinity Health and Wellness Center/AIDS Arms, Inc.
Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
Dallas : 1220.19.0012 Boehringer Ingelheim Investigational Site
Phase III Trial of BI 201335 in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)- Human Immunodeficiency Virus (HIV) Coinfected Patients
Dallas : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Dallas : Dallas VA Medical Center
Raltegravir And Darunavir Antiretroviral in Antiretroviral Naive Patients
Dallas : Parkland Health & Hospital System
Raltegravir And Darunavir Antiretroviral in Antiretroviral Naive Patients
Dallas : Amelia Court Hiv Research Clinic
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Dallas : North Texas Infectious Disease Consultants
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
Dallas : UT Southwestern Clinical Research Unit
Strategic Timing of Antiretroviral Treatment
Dallas : GSK Investigational Site
Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and/or Elivitegravir
Dallas : Uptown Physicians Group
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Dallas : Southwest Infectious Disease Clinical Research, Inc
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Dallas : UT Southwestern Medical Center
Therapeutic Approaches to HAART-Induced Lipodystrophy
Fort Sam Houston : San Antonio Military Health System
Strategic Timing of Antiretroviral Treatment
Fort Worth : Tarrant County Infectious Disease Associates
Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment
Fort Worth : Tarrant County Infectious Disease Associates
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Fort Worth : Tarrant County Infectious Disease
Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
Fort Worth : 1220.19.0060 Boehringer Ingelheim Investigational Site
Phase III Trial of BI 201335 in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)- Human Immunodeficiency Virus (HIV) Coinfected Patients
Fort Worth : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Fort Worth : Tarrant County Infectious Disease Associates
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
Fort Worth : University of North Texas Health Science Center
Strategic Timing of Antiretroviral Treatment
Fort Worth : Tarrant County Infectious Disease Associates
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Harlingen : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Houston : Therapeutic Concepts, PA
A Pilot Study of Kaletra and Intelence Tablets in Naive Subjects
Houston : GSK Investigational Site
A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
Houston : Texas
A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)
Houston : Texas Children's Hosp. CRS (3801) Updated
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Houston : Houston AIDS Research Team CRS (31473)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
Houston : Therapeutic Concepts, PA
Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment
Houston : Therapeutic Concepts
Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus
Houston : Gordon E. Crofoot MD, PA
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Houston : Therapeutic Concepts PA
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Houston : Gordon Crofoot MD, PA
Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
Houston : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Houston : Baylor College Of Medicine
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Houston : Texas Children's Hospital
Strategic Timing of Antiretroviral Treatment
Houston : Houston AIDS Research Team CRS
Strategic Timing of Antiretroviral Treatment
Houston : St. Hope Foundation Inc
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Houston : Therapeutic Concepts, PA
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Houston : Gordon Crofoot Md, Pa
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Houston : The University of Texas Health Science Center at Houston
Truvada Plus Raltegravir for Nonoccupational Post-exposure Prophylaxis (nPEP)
Longview :
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Etravirine Administered in Combination With Other Antiretroviral Agents in Antiretroviral Treatment-Experienced HIV-1 Infected Patients
Longview : Dcol Center For Clinical Research
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
Longview : DCOL Center for Clinical Research
Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
Longview : DCOL Center for Clinical Research
Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults
San Antonio : 1220.19.0016 Boehringer Ingelheim Investigational Site
Phase III Trial of BI 201335 in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)- Human Immunodeficiency Virus (HIV) Coinfected Patients
San Antonio : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
San Antonio : Alamo Medical Research
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Virginia
Annandale : GSK Investigational Site
A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
Annandale : Clinical Alliance for Research & Education - Infectious Disease
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Annandale : Clinical Alliance for Research & Education - Infectious Diseases, LLC (CARE-ID)
Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
Annandale : 1220.19.0001 Boehringer Ingelheim Investigational Site
Phase III Trial of BI 201335 in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)- Human Immunodeficiency Virus (HIV) Coinfected Patients
Annandale : CARE-ID
Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults
View More »
Annandale : GSK Investigational Site
Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and/or Elivitegravir
Danville : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Lynchburg : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Richmond : Pfizer Investigational Site
An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children
Richmond : Virginia Commonwealth Univ. Medical Ctr. CRS (31475)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
Richmond : 1220.19.0026 Boehringer Ingelheim Investigational Site
Phase III Trial of BI 201335 in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)- Human Immunodeficiency Virus (HIV) Coinfected Patients
Richmond : Virginia Commonwealth University
Strategic Timing of Antiretroviral Treatment
Washington
Seattle : GSK Investigational Site
A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
Seattle : Washington
A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)
Seattle : University of Washington NICHD CRS (5029) Updated
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Seattle : Harborview Medical Center NICHD CRS (5027) Updated
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Seattle : Seattle Children's Hospital NICHD CRS (5017) Updated
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
View More »
Seattle : University of Washington AIDS CRS (1401)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
Seattle : GSK Investigational Site
Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine
Seattle : Peter Shalit, M.D.
Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
Seattle : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Seattle : University of Washington Primary Infection Clinic
Raltegravir (Isentress/MK-0518) and HIV-1 Infected CD4 Cells During Acute/Early HIV-1
West Virginia
Huntington : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Wisconsin
Madison : University of Wisconsin Hospital and Clinics
A Pilot Study to Examine the Feasibility and Effect of Tumor Necrosis Factor (TNF) Inhibition on HIV Disease
Madison : University of Wisconsin Hospital and Clinics
Nelfinavir and M8 Drug-Level Monitoring in HIV-1 Infection
Milwaukee : AIDS Resource Center of Wisconsin
Strategic Timing of Antiretroviral Treatment
Milwaukee : Medical College of Wisconsin
Strategic Timing of Antiretroviral Treatment
Argentina
Buenos Aires :
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Etravirine Administered in Combination With Other Antiretroviral Agents in Antiretroviral Treatment-Experienced HIV-1 Infected Patients
Buenos Aires : Local Institution
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
Buenos Aires : FUNCEI
Strategic Timing of Antiretroviral Treatment
Buenos Aires : Hospital General de Agudos JM Ramos Mejia
Strategic Timing of Antiretroviral Treatment
Buenos Aires : Hospital General de Agudos 'Dr. Teodoro Alvarez'
Strategic Timing of Antiretroviral Treatment
View More »
Buenos Aires : Hospital Interzonal General de Agudos Dr. Diego Paroissien
Strategic Timing of Antiretroviral Treatment
Buenos Aires : Hospital Italiano de Buenos Aires
Strategic Timing of Antiretroviral Treatment
Buenos Aires :
TMC114-TiDP29-C232 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir (Rtv) for Children Coming From Any of the Three Ongoing Tibotec Sponsored Pediatric Studies With DRV
Buenos Aires, Bs As : Local Institution
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
Buenos Aires, Bs As : Local Institution
Phase IIIB Pediatric ATV Powder for Oral Use (POU) (PRINCE2)
C 1249 Abp - Buenos Aires :
TMC114-TiDP29-C232 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir (Rtv) for Children Coming From Any of the Three Ongoing Tibotec Sponsored Pediatric Studies With DRV
Ciudad Autonoma de Buenos Aires : CEADI
Strategic Timing of Antiretroviral Treatment
Ciudad Autonoma de Buenos Aires : Fundacion IDEAA
Strategic Timing of Antiretroviral Treatment
Ciudad De Buenos Aires : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Ciudad de Buenos Aires : Fundacion Huesped
Study of Lopinavir/ Ritonavir and Lamivudine Versus Standard Therapy in Naïve HIV-1 Infected Subjects.
Cordoba : Local Institution
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
Cordoba : Hospital Rawson
Strategic Timing of Antiretroviral Treatment
El Palomar : Hospital Nacional Profesor Alejandro Posadas
Strategic Timing of Antiretroviral Treatment
Prov De Santa Fe : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Rosario :
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Etravirine Administered in Combination With Other Antiretroviral Agents in Antiretroviral Treatment-Experienced HIV-1 Infected Patients
Rosario : Local Institution
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
Rosario : CAICI
Strategic Timing of Antiretroviral Treatment
Australia
Adelaide : Royal Adelaide Hospital
Strategic Timing of Antiretroviral Treatment
Adelaide : O'Brien Street Practice
Strategic Timing of Antiretroviral Treatment
Brisbane : AIDS Medical Unit
Strategic Timing of Antiretroviral Treatment
Burwood : Burwood Road General Practice
Strategic Timing of Antiretroviral Treatment
Cairns North : Cairns Sexual Health Service
Strategic Timing of Antiretroviral Treatment
View More »
Darlinghurst : Taylor Square Private Clinic
Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment
Darlinghurst : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Darlinghurst : Local Institution
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
Darlinghurst : Holdsworth House Medical Practice
Strategic Timing of Antiretroviral Treatment
Darlinghurst : St. Vincent's Hospital
Strategic Timing of Antiretroviral Treatment
Darlinghurst : Taylor Square Private Clinic
Strategic Timing of Antiretroviral Treatment
Darlinghurst Nsw : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Melbourne : The Alfred Hospital
A Surveillance Program for the Detection of Hepatitis B Virus (HBV) Resistance to Tenofovir in HIV-HBV co-Infected Patients
Melbourne : Infectious Diseases Unit - The Alfred Hospital
Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment
Melbourne : The Alfred Hospital
HIV-HBV Co-Infection and Liver Disease
Melbourne : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Melbourne : Melbourne Sexual Health Centre
Strategic Timing of Antiretroviral Treatment
Melbourne : Prahran Market Clinic
Strategic Timing of Antiretroviral Treatment
Melbourne : The Alfred Hospital
Strategic Timing of Antiretroviral Treatment
Perth : Royal Perth Hospital
Strategic Timing of Antiretroviral Treatment
St. Kilda : Centre Clinic
Strategic Timing of Antiretroviral Treatment
Sydney : Holdsworth House Medical Practice
Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment
Sydney : 407 Doctors
Once Daily 3TC, Efavirenz and ddI for HIV Infection
Sydney : St. Vincent's Hospital, 390 Victoria Rd, Darlinghurst
Raltegravir Use as Nonoccupational Postexposure Prophylaxis (NPEP) in Men Who Have Sex With Men
Sydney : East Sydney Doctors
Strategic Timing of Antiretroviral Treatment
Westmead : Westmead Hospital
Strategic Timing of Antiretroviral Treatment
Austria
Graz : Landeskrankenhaus Graz West
Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment
Graz : Boehringer Ingelheim Investigational Site 6
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Salzburg : Boehringer Ingelheim Investigational Site 5
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Vienna : Boehringer Ingelheim Investigational Site 2
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Vienna : Boehringer Ingelheim Investigational Site 3
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
View More »
Vienna : Boehringer Ingelheim Investigational Site 1
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Vienna : University Vienna General Hospital
Strategic Timing of Antiretroviral Treatment
Wels : Boehringer Ingelheim Investigational Site 4
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Wien : Otto Wagner Spital
Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment
Wien : Allgemeines Krankenhaus
Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment
Wien : Otto-Wagner-Spital SMZ /Baumgartner Hoehe
Strategic Timing of Antiretroviral Treatment
Belgium
Antwerp : Institute of Tropical Medicine
Strategic Timing of Antiretroviral Treatment
Antwerp : Site Reference ID/Investigator# 27827
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Antwerpen :
A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment
Antwerpen :
A Trial With TMC278-TIDP6-C222 for Continued TMC278 Access in Patients Infected With Human Immunodeficiency Virus-1
Antwerpen : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
View More »
Antwerpen : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Brussels :
A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment
Brussels :
A Trial With TMC278-TIDP6-C222 for Continued TMC278 Access in Patients Infected With Human Immunodeficiency Virus-1
Brussels : Saint-Pierre University Hospital; Department of Infectious Diseases
Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.
Brussels : Hospital St Pierre
Post-marketing Safety Surveillance Program in Human Immunodeficiency Virus (HIV)-Infected Children Exposed to Atazanavir in Europe
Brussels : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Brussels : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Brussels : Site Reference ID/Investigator# 6129
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Bruxelles :
A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment
Bruxelles : GSK Investigational Site
A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
Bruxelles :
A Trial With TMC278-TIDP6-C222 for Continued TMC278 Access in Patients Infected With Human Immunodeficiency Virus-1
Bruxelles : Centre Hospitalier Universitaire St. Pierre (C.H.U. St. Pierre)
Strategic Timing of Antiretroviral Treatment
Charleroi : Site Reference ID/Investigator# 27825
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Gent :
A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment
Gent :
A Trial With TMC278-TIDP6-C222 for Continued TMC278 Access in Patients Infected With Human Immunodeficiency Virus-1
Gent : Universitaire Ziekenhuizen Gent
Strategic Timing of Antiretroviral Treatment
Ghent : Site Reference ID/Investigator# 27823
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Leuven :
A Trial With TMC278-TIDP6-C222 for Continued TMC278 Access in Patients Infected With Human Immunodeficiency Virus-1
Leuven : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Leuven : Universitair Ziekenhuis Gasthuisberg
Strategic Timing of Antiretroviral Treatment
Leuven : Site Reference ID/Investigator# 27822
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Liege : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Liege : Site Reference ID/Investigator# 27824
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Liege : Site Reference ID/Investigator# 27826
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Liege : CHU Sart Tilman
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Botswana
Brazil
Belo Horizonte : SOM Federal University Minas Gerais Brazil NICHD CRS (5073) Updated
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Campinas : GSK Investigational Site
Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females
Porto Alegre : GSK Investigational Site
Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females
Porto Alegre : Local Institution
Phase IIIB Pediatric ATV Powder for Oral Use (POU) (PRINCE2)
Recife : Local Institution
Phase IIIB Pediatric ATV Powder for Oral Use (POU) (PRINCE2)
View More »
Ribeirao Preto : Local Institution
Phase IIIB Pediatric ATV Powder for Oral Use (POU) (PRINCE2)
Ribeirao Preto :
TMC114-TiDP29-C232 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir (Rtv) for Children Coming From Any of the Three Ongoing Tibotec Sponsored Pediatric Studies With DRV
Rio de Janeiro : Hospital dos Servidores Rio de Janeiro NICHD CRS (5072) Updated
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Rio de Janeiro : Hospital Geral De Nova Igaucu Brazil NICHD CRS (5097) Updated
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Rio de Janeiro : Universidade Federal do Rio de Janeiro NICHD CRS (5071) Updated
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Rio de Janeiro : Instituto de Pesquisa Clinica Evandro Chagas (IPEC)
An Evaluation of the Pharmacological Interaction of Lopinavir/r and Rifampin
Rio de Janeiro : Hospital Escola Sao Francisco de Assis - UFRJ
Strategic Timing of Antiretroviral Treatment
Rio de Janeiro : Ipec/Fiocruz
Strategic Timing of Antiretroviral Treatment
Rio De Janeiro :
TMC114-TiDP29-C232 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir (Rtv) for Children Coming From Any of the Three Ongoing Tibotec Sponsored Pediatric Studies With DRV
Salvador : SEI - Servicos Especializados em Infectologia
Strategic Timing of Antiretroviral Treatment
Sao Paolo : Local Institution
Phase IIIB Pediatric ATV Powder for Oral Use (POU) (PRINCE2)
Sao Paulo : Univ of Sao Paulo Brazil NICHD CRS (5074) Updated
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Sao Paulo : Centro de Referencia e Treinamento DST/Aids
Strategic Timing of Antiretroviral Treatment
Sao Paulo : Instituto de Infectologia Emilio Ribas - IIER
Strategic Timing of Antiretroviral Treatment
Sao Paulo : Lim 56/Hcfmusp
Strategic Timing of Antiretroviral Treatment
Sao Paulo :
TMC114-TiDP29-C232 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir (Rtv) for Children Coming From Any of the Three Ongoing Tibotec Sponsored Pediatric Studies With DRV
São Paulo : Pfizer Investigational Site
An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children
Vitoria : University of Espirito Santo
An Evaluation of the Pharmacological Interaction of Lopinavir/r and Rifampin
Burkina Faso
Bobo Dioulasso : Day Hospital, CHU Sanou Souro
Evaluation of Three Strategies of Second-line Antiretroviral Treatment in Africa (Dakar - Bobo-Dioulasso - Yaoundé)
Cameroon
Yaounde : Day Hospital, Central Hospital
Evaluation of Three Strategies of Second-line Antiretroviral Treatment in Africa (Dakar - Bobo-Dioulasso - Yaoundé)
Canada
Edmonton : Edmonton
A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)
Edmonton : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Halifax : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Montreal : GSK Investigational Site
A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
Montreal : Montreal
A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)
View More »
Montreal : Clinique Medicale du Quartier Latin
Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment
Montreal : Clinique Medicale Du Quartier Latin
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Montreal : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Montreal : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Montreal : Local Institution
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
Montreal : Clinique Medicale Du Quartier Latin
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Montreal : Immunodeficiency Service Montreal Chest Institute McGill University Health Centre
Trial of Citalopram for the Prevention of Depression
Montréal : Clinique médicale l'Actuel
Safety and Efficacy Study of AGS-004 During Analytical Treatment Interruption
Montréal : Clinique Médical du Quartier Latin
Safety and Efficacy Study of AGS-004 During Analytical Treatment Interruption
Montréal : Montreal Chest Institute, Immunodeficiency Dept.
Safety and Efficacy Study of AGS-004 During Analytical Treatment Interruption
Ottawa : The Ottawa Hospital
Safety and Efficacy Study of AGS-004 During Analytical Treatment Interruption
Toronto : Sunnybrook Health Sciences Center
Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment
Toronto : Maple Leaf Medical Clinic
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Toronto : Sunnybrook Health Sciences Center
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Toronto : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Toronto : Maple Leaf Medical Clinic
Study to Assess Safety and Quality of Life of Patients Using Biojector Versus Needles for Fuzeon Administration
Toronto : Sunnybrook Health Sciences Centre
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Vancouver : GSK Investigational Site
A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
Vancouver : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Vancouver : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Victoria : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Chile
Santiago : Local Institution
Phase IIIB Pediatric ATV Powder for Oral Use (POU) (PRINCE2)
Santiago : Fundacion Arriaran
Strategic Timing of Antiretroviral Treatment
China
Beijing : Division of Treatment and Care, NCAIDS, China CDC
A Trial to Compare Raltegravir Versus Nevirapine as Anchor Drug for HIV+ Chinese IDUs on Methadone Maintenance
Colombia
Bogota : Local Institution
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
Bogota : Asistencia Cientifica de Alta Complejidad
Pregabalin Trial In HIV Neuropathic Pain
Bogota D.C. : Riesgo de Fractura S.A.
Pregabalin Trial In HIV Neuropathic Pain
Côte D'Ivoire
Abidjan : Centre de prise en charge de personnes vivant avec le VIH la pierre angulaire
Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults (ANRS 12136 TEMPRANO)
Abidjan : Centre de Prise en Charge et de Formation ACONDA
Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults (ANRS 12136 TEMPRANO)
Abidjan : Centre de Suivi des donneurs de sang, Centre National de Transfusion Sanguine
Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults (ANRS 12136 TEMPRANO)
Abidjan : Hopital Général Felix Houphouet Boigny
Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults (ANRS 12136 TEMPRANO)
Abidjan : Service des Maladies Infectieuses et Tropicales, CHU de Treichville
Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults (ANRS 12136 TEMPRANO)
View More »
Abidjan : Unité de Soins Ambulatoires et de Conseil, CHU de Treichville
Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults (ANRS 12136 TEMPRANO)
Abidjan : Centre Intégré de Recherches Biocliniques d'Abidjan
Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults (ANRS 12136 TEMPRANO)
Abidjan : Formation Sanitaire Urbaine Anonkoua Kouté
Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults (ANRS 12136 TEMPRANO)
Czech Republic
Denmark
Aarhus : Arhus Universitetshospital, Skejby
Strategic Timing of Antiretroviral Treatment
Copenhagen :
A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment
Copenhagen : Rigshospitalet, Department of Infectious Diseases, M5112 CRS
Strategic Timing of Antiretroviral Treatment
Hvidovre : Hvidovre University Hospital, Department of Infectious Diseases CRS
Strategic Timing of Antiretroviral Treatment
Hvidovre N/A :
A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment
View More »
Odense : Odense University Hospital
Strategic Timing of Antiretroviral Treatment
Dominican Republic
Santo Domingo : Instituto Dominicano de Estudio Virologicos
Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment
Estonia
Finland
France
Aulnay-sous-Bois : GSK Investigational Site
A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
Besancon : CHU de BESANCON - Hopital Saint Jacques
Strategic Timing of Antiretroviral Treatment
Bobigny : GSK Investigational Site
A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
Bobigny :
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Etravirine Administered in Combination With Other Antiretroviral Agents in Antiretroviral Treatment-Experienced HIV-1 Infected Patients
Bondy : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
View More »
Bordeaux : GSK Investigational Site
A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
Bordeaux : CHU de Bordeaux
Efficacy and Safety of Varenicline Among HIV-infected Patients
Bordeaux : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Caen : CHU De Caen, Service de Néphrologie Hémodialyse
Renal Transplantation and Raltegravir in HIV-Infected Patients
Caen : CHU Cote de Nacre
Strategic Timing of Antiretroviral Treatment
Clamart : Valerie Martinez
Lenalidomide in Kaposi Disease Associated With HIV Infection
Clamart : Hopital Antoine Beclere
Strategic Timing of Antiretroviral Treatment
Creteil : Hôpital Henri Mondor
Immuno-stimulation With Maraviroc Combined to Antiretroviral Therapy in Advanced Late Diagnosed HIV-1 Infected Patients
Creteil : Hopital Henri Mondor
Strategic Timing of Antiretroviral Treatment
Créteil : GSK Investigational Site
Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine
Créteil : Hôpital Henri Mondor, Service de Néphrologie Transplantation
Renal Transplantation and Raltegravir in HIV-Infected Patients
Dijon cedex : 1220.19.3302 Boehringer Ingelheim Investigational Site
Phase III Trial of BI 201335 in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)- Human Immunodeficiency Virus (HIV) Coinfected Patients
Garches : GSK Investigational Site
A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
Garches : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Gonesse cedex : GSK Investigational Site
A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
Kremlin Bicetre : Hopital de Bicetre
Strategic Timing of Antiretroviral Treatment
Kremlin Bicêtre : Hôpital Kremlin Bicêtre, Service de Néphrologie
Renal Transplantation and Raltegravir in HIV-Infected Patients
Lyon :
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Etravirine Administered in Combination With Other Antiretroviral Agents in Antiretroviral Treatment-Experienced HIV-1 Infected Patients
Lyon : 1220.19.3306 Boehringer Ingelheim Investigational Site
Phase III Trial of BI 201335 in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)- Human Immunodeficiency Virus (HIV) Coinfected Patients
Lyon Cedex 02 : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Marseille : GSK Investigational Site
A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
Marseille : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Marseille Cedex 08 : 1220.19.3303 Boehringer Ingelheim Investigational Site
Phase III Trial of BI 201335 in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)- Human Immunodeficiency Virus (HIV) Coinfected Patients
Marseille Cedex 09 : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Marseille cedex 9 : 1220.19.3304 Boehringer Ingelheim Investigational Site
Phase III Trial of BI 201335 in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)- Human Immunodeficiency Virus (HIV) Coinfected Patients
Montpellier Cedex 5 : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Nantes :
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Etravirine Administered in Combination With Other Antiretroviral Agents in Antiretroviral Treatment-Experienced HIV-1 Infected Patients
Nantes : GSK Investigational Site
Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine
Nice : GSK Investigational Site
A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
Nice :
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Etravirine Administered in Combination With Other Antiretroviral Agents in Antiretroviral Treatment-Experienced HIV-1 Infected Patients
Orléans Cedex 2 : GSK Investigational Site
A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
Paris : GSK Investigational Site
A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
Paris :
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Etravirine Administered in Combination With Other Antiretroviral Agents in Antiretroviral Treatment-Experienced HIV-1 Infected Patients
Paris : Hôpital Pitié Salpétrière
Evaluation of Raltegravir Plus Maraviroc Therapy in Controlled HIV Patients Presenting With Lipohypertrophy
Paris : GSK Investigational Site
Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine
Paris : CIC Cochin Pasteur
Phase I/IIa Dose-escalation Clinical Study of VAC-3S
Paris : Hopital Pitie Salpetriere
Phase I/IIa Dose-escalation Clinical Study of VAC-3S
Paris : 1220.19.3301 Boehringer Ingelheim Investigational Site
Phase III Trial of BI 201335 in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)- Human Immunodeficiency Virus (HIV) Coinfected Patients
Paris : 1220.19.3305 Boehringer Ingelheim Investigational Site
Phase III Trial of BI 201335 in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)- Human Immunodeficiency Virus (HIV) Coinfected Patients
Paris : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Paris : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Paris : Hopital Hotel Dieu
Strategic Timing of Antiretroviral Treatment
Paris : Hopital Europeen Georges Pompidou
Strategic Timing of Antiretroviral Treatment
Paris : Hopital Saint-Louis
Strategic Timing of Antiretroviral Treatment
Paris : Hopital Saint-Antoine
Strategic Timing of Antiretroviral Treatment
Paris : Groupe Hospitalier Pitie-Salpetriere
Strategic Timing of Antiretroviral Treatment
Paris :
TMC114-TiDP29-C232 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir (Rtv) for Children Coming From Any of the Three Ongoing Tibotec Sponsored Pediatric Studies With DRV
Paris : Hopital Cochin CIC de vaccinologie
Trial Comparing Three Strategies of Vaccination Against the Virus of Hepatitis B in HIV Infected Patients
Paris Cedex 10 : GSK Investigational Site
A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
Paris Cedex 10 : GSK Investigational Site
Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine
Paris Cedex 10 : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Paris Cedex 10 : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Paris Cedex 12 :
A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment
Paris Cedex 12 : GSK Investigational Site
Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine
Paris Cedex 12 : 1220.19.3307 Boehringer Ingelheim Investigational Site
Phase III Trial of BI 201335 in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)- Human Immunodeficiency Virus (HIV) Coinfected Patients
Paris Cedex 13 : GSK Investigational Site
A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
Paris Cedex 13 : GSK Investigational Site
Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine
Paris cedex 14 : GSK Investigational Site
A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
Paris CEDEX 14 : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Paris cedex 15 : GSK Investigational Site
A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
Paris cedex 15 : GSK Investigational Site
Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine
Paris Cedex 18 : 1220.19.3308 Boehringer Ingelheim Investigational Site
Phase III Trial of BI 201335 in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)- Human Immunodeficiency Virus (HIV) Coinfected Patients
Paris Cedex 20 : GSK Investigational Site
A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
Paris Cedex 20 : GSK Investigational Site
Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine
Paris, 75 : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Perpignan : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Pessac : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Pessac Cedex : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Rennes : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Suresnes : Hopital Foch
Strategic Timing of Antiretroviral Treatment
Toulon : Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer, Service d'infectiologie
IntensVIH: Impact Of Therapy Intensification By An Integrase Inhibitor +/- CCR5 Inhibitor On The Lymphoid Reservoir For Hiv-1 In Chronically Infected Patients
Toulon : Centre Hospitalier Intercommunal de Toulon La Seyne sur mer
IntensVIH: Impact Of Therapy Intensification By An Integrase Inhibitor +/- CCR5 Inhibitor On The Lymphoid Reservoir For Hiv-1 In Chronically Infected Patients
Tourcoing : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Tourcoing : Hopital Gustave Dron
Strategic Timing of Antiretroviral Treatment
Villejuif : Département de Médecine Interne et Maladies Infectieuses, Hôpital Paul Brousse
Raltegravir in Patients With End Stage Liver Disease and in Transplant Recipients
Germany
Aachen : Site Reference ID/Investigator# 28228
Kaletra in Combination With Integrase Inhibitors
Aachen : Boehringer Ingelheim Investigational Site 25
Non-interventional Observational Study With Viramune in HIV to Evaluate Gender Specific Data
Aachen : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Aachen : Local Institution
Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting
Aachen : Site Reference ID/Investigator# 28521
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
View More »
Berlin :
A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment
Berlin : EPIMED GmbH
Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment
Berlin : Local Institution
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
Berlin : Site Reference ID/Investigator# 30764
Kaletra in Combination With Integrase Inhibitors
Berlin : Site Reference ID/Investigator# 47155
Kaletra in Combination With Integrase Inhibitors
Berlin : Site Reference ID/Investigator# 28185
Kaletra in Combination With Integrase Inhibitors
Berlin : Site Reference ID/Investigator# 28199
Kaletra in Combination With Integrase Inhibitors
Berlin : Site Reference ID/Investigator# 28229
Kaletra in Combination With Integrase Inhibitors
Berlin : Site Reference ID/Investigator# 28249
Kaletra in Combination With Integrase Inhibitors
Berlin : Site Reference ID/Investigator# 28260
Kaletra in Combination With Integrase Inhibitors
Berlin : Site Ref # / Investigator 63682
Kaletra in Combination With Integrase Inhibitors
Berlin : Site Reference ID/Investigator# 30762
Kaletra in Combination With Integrase Inhibitors
Berlin : Site Reference ID/Investigator# 30763
Kaletra in Combination With Integrase Inhibitors
Berlin : Site Reference ID/Investigator# 28183
Kaletra in Combination With Integrase Inhibitors
Berlin : Site Reference ID/Investigator# 28205
Kaletra in Combination With Integrase Inhibitors
Berlin : Site Reference ID/Investigator# 28243
Kaletra in Combination With Integrase Inhibitors
Berlin : GSK Investigational Site
Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine
Berlin : Boehringer Ingelheim Investigational Site 8
Non-interventional Observational Study With Viramune in HIV to Evaluate Gender Specific Data
Berlin : Boehringer Ingelheim Investigational Site 9
Non-interventional Observational Study With Viramune in HIV to Evaluate Gender Specific Data
Berlin : Boehringer Ingelheim Investigational Site 10
Non-interventional Observational Study With Viramune in HIV to Evaluate Gender Specific Data
Berlin : Boehringer Ingelheim Investigational Site 14
Non-interventional Observational Study With Viramune in HIV to Evaluate Gender Specific Data
Berlin : Boehringer Ingelheim Investigational Site 32
Non-interventional Observational Study With Viramune in HIV to Evaluate Gender Specific Data
Berlin : Boehringer Ingelheim Investigational Site 4
Non-interventional Observational Study With Viramune in HIV to Evaluate Gender Specific Data
Berlin : Boehringer Ingelheim Investigational Site 11
Non-interventional Observational Study With Viramune in HIV to Evaluate Gender Specific Data
Berlin : Boehringer Ingelheim Investigational Site 21
Non-interventional Observational Study With Viramune in HIV to Evaluate Gender Specific Data
Berlin : Boehringer Ingelheim Investigational Site 28
Non-interventional Observational Study With Viramune in HIV to Evaluate Gender Specific Data
Berlin : Boehringer Ingelheim Investigational Site 30
Non-interventional Observational Study With Viramune in HIV to Evaluate Gender Specific Data
Berlin : Boehringer Ingelheim Investigational Site 38
Non-interventional Observational Study With Viramune in HIV to Evaluate Gender Specific Data
Berlin : Boehringer Ingelheim Investigational Site 5
Non-interventional Observational Study With Viramune in HIV to Evaluate Gender Specific Data
Berlin :
Occupational Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r) (PEPDar)
Berlin : CHARITÉ Berlin
Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.
Berlin : 1220.19.4921 Boehringer Ingelheim Investigational Site
Phase III Trial of BI 201335 in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)- Human Immunodeficiency Virus (HIV) Coinfected Patients
Berlin : 1220.19.4902 Boehringer Ingelheim Investigational Site
Phase III Trial of BI 201335 in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)- Human Immunodeficiency Virus (HIV) Coinfected Patients
Berlin : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Berlin : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Berlin : EPIMED-Gesellschaft fuer epidemiologische und klinische Forschung in der MedizinmbH
Strategic Timing of Antiretroviral Treatment
Berlin : Gemeinschaftspraxis Jessen-Jessen-Stein
Strategic Timing of Antiretroviral Treatment
Berlin : Local Institution
Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting
Berlin : Site Reference ID/Investigator# 47146
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Berlin : Site Reference ID/Investigator# 28484
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Berlin : Site Reference ID/Investigator# 28485
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Berlin : Site Reference ID/Investigator# 28486
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Berlin : Site Reference ID/Investigator# 28496
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Berlin : Site Reference ID/Investigator# 28503
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Berlin : Site Reference ID/Investigator# 28514
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Berlin : Site Reference ID/Investigator# 28522
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Berlin : Site Reference ID/Investigator# 28557
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Berlin : Site Reference ID/Investigator# 28567
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Berlin : Site Reference ID/Investigator# 29154
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Berlin : Site Reference ID/Investigator# 32383
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Berlin : Site Reference ID/Investigator# 32384
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Berlin : Site Reference ID/Investigator# 59472
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Berlin : Site Reference ID/Investigator# 29271
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Berlin : Site Reference ID/Investigator# 28559
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Berlin : Site Reference ID/Investigator# 28569
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Berlin : Site Reference ID/Investigator# 29147
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Berlin : Site Reference ID/Investigator# 28518
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Berlin : Site Reference ID/Investigator# 28494
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Berlin : Site Reference ID/Investigator# 28504
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Bochum : GSK Investigational Site
Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine
Bochum : Site Reference ID/Investigator# 28488
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Bonn : Univeristy of Bonn, Medical Department 1
Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment
Bonn :
Occupational Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r) (PEPDar)
Bonn : University of Bonn
Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.
Bonn : 1220.19.4901 Boehringer Ingelheim Investigational Site
Phase III Trial of BI 201335 in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)- Human Immunodeficiency Virus (HIV) Coinfected Patients
Bonn : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Bonn : Medizinische Universitaetsklinik - Bonn, Immunologische Ambulanz CRS
Strategic Timing of Antiretroviral Treatment
Bonn : Site Reference ID/Investigator# 28562
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Bremen : Site Reference ID/Investigator# 28224
Kaletra in Combination With Integrase Inhibitors
Bremen : Site Reference ID/Investigator# 29269
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Bremen : Site Reference ID/Investigator# 59469
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Chemnitz : Boehringer Ingelheim Investigational Site 36
Non-interventional Observational Study With Viramune in HIV to Evaluate Gender Specific Data
Cologne : Site Reference ID/Investigator# 28252
Kaletra in Combination With Integrase Inhibitors
Cologne : University of Cologne
Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.
Cologne : Site Reference ID/Investigator# 28554
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Cologne : Site Reference ID/Investigator# 28495
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Cologne : Site Reference ID/Investigator# 29262
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Cologne : Site Reference ID/Investigator# 28571
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Cologne : Site Reference ID/Investigator# 28563
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Dortmund : Site Ref # / Investigator 28223
Kaletra in Combination With Integrase Inhibitors
Dortmund : Site Reference ID/Investigator# 28184
Kaletra in Combination With Integrase Inhibitors
Dortmund : Boehringer Ingelheim Investigational Site 34
Non-interventional Observational Study With Viramune in HIV to Evaluate Gender Specific Data
Dortmund :
Occupational Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r) (PEPDar)
Dortmund : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Dortmund : Infectious Diseases and Pneumology Klinikum Dortmund gGmbH
Strategic Timing of Antiretroviral Treatment
Dortmund : Site Reference ID/Investigator# 47142
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Dortmund : Site Reference ID/Investigator# 28516
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Dresden : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Duesseldorf : Site Ref # / Investigator 63685
Kaletra in Combination With Integrase Inhibitors
Duesseldorf : Site Reference ID/Investigator# 28250
Kaletra in Combination With Integrase Inhibitors
Duesseldorf : Site Reference ID/Investigator# 28547
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Duesseldorf : Site Reference ID/Investigator# 28491
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Duisburg : Site Reference ID/Investigator# 28231
Kaletra in Combination With Integrase Inhibitors
Duisburg : Site Reference ID/Investigator# 28524
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Dusseldorf : Universitaetsklinikum Duesseldorf
Strategic Timing of Antiretroviral Treatment
Dusseldorf : Local Institution
Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting
Düsseldorf : Boehringer Ingelheim Investigational Site 31
Non-interventional Observational Study With Viramune in HIV to Evaluate Gender Specific Data
Erlangen : GSK Investigational Site
Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine
Erlangen :
Occupational Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r) (PEPDar)
Erlangen : Universitaetsklinikum Erlangen
Strategic Timing of Antiretroviral Treatment
Essen : Site Reference ID/Investigator# 28194
Kaletra in Combination With Integrase Inhibitors
Essen : Klinik fur Dermatologie, Venerologie, Allergologie
Strategic Timing of Antiretroviral Treatment
Frankfurt :
A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment
Frankfurt : Site Reference ID/Investigator# 28233
Kaletra in Combination With Integrase Inhibitors
Frankfurt : Site Reference ID/Investigator# 28227
Kaletra in Combination With Integrase Inhibitors
Frankfurt : Boehringer Ingelheim Investigational Site 1
Non-interventional Observational Study With Viramune in HIV to Evaluate Gender Specific Data
Frankfurt : Boehringer Ingelheim Investigational Site 18
Non-interventional Observational Study With Viramune in HIV to Evaluate Gender Specific Data
Frankfurt : Boehringer Ingelheim Investigational Site 19
Non-interventional Observational Study With Viramune in HIV to Evaluate Gender Specific Data
Frankfurt :
Occupational Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r) (PEPDar)
Frankfurt : German Competence Network
Post-marketing Safety Surveillance Program in Human Immunodeficiency Virus (HIV)-Infected Children Exposed to Atazanavir in Europe
Frankfurt : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Frankfurt : Johann Wolfgang Goethe - University Hospital, Infektionsambulanz CRS
Strategic Timing of Antiretroviral Treatment
Frankfurt : Site Reference ID/Investigator# 28545
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Frankfurt : Site Reference ID/Investigator# 29270
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Frankfurt : Site Reference ID/Investigator# 28520
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Frankfurt am Main : Site Ref # / Investigator 54202
Kaletra in Combination With Integrase Inhibitors
Frankfurt am Main : Johann Wolfgang Goethe-Universität
Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.
Frankfurt am Main : 1220.19.4924 Boehringer Ingelheim Investigational Site
Phase III Trial of BI 201335 in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)- Human Immunodeficiency Virus (HIV) Coinfected Patients
Frankfurt am Main : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Frankfurt Am Main : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Frankfurt am Main : Site Reference ID/Investigator# 29260
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Freiburg : Site Reference ID/Investigator# 28246
Kaletra in Combination With Integrase Inhibitors
Freiburg : Site Reference ID/Investigator# 28258
Kaletra in Combination With Integrase Inhibitors
Freiburg : GSK Investigational Site
Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine
Freiburg : Boehringer Ingelheim Investigational Site 2
Non-interventional Observational Study With Viramune in HIV to Evaluate Gender Specific Data
Freiburg :
Occupational Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r) (PEPDar)
Freiburg : Local Institution
Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting
Freiburg : Site Reference ID/Investigator# 29266
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Freiburg : Site Reference ID/Investigator# 28550
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Freiburg : Site Reference ID/Investigator# 28564
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Fuerth : Site Reference ID/Investigator# 28251
Kaletra in Combination With Integrase Inhibitors
Fuerth : Site Reference ID/Investigator# 28570
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Giessen : Site Reference ID/Investigator# 28193
Kaletra in Combination With Integrase Inhibitors
Giessen : Site Reference ID/Investigator# 28196
Kaletra in Combination With Integrase Inhibitors
Giessen : Boehringer Ingelheim Investigational Site 39
Non-interventional Observational Study With Viramune in HIV to Evaluate Gender Specific Data
Giessen : Site Reference ID/Investigator# 28498
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Halle : Site Reference ID/Investigator# 28261
Kaletra in Combination With Integrase Inhibitors
Hamburg : Local Institution
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
Hamburg : Site Reference ID/Investigator# 28256
Kaletra in Combination With Integrase Inhibitors
Hamburg : Site Reference ID/Investigator# 47154
Kaletra in Combination With Integrase Inhibitors
Hamburg : Site Reference ID/Investigator# 28202
Kaletra in Combination With Integrase Inhibitors
Hamburg : Site Reference ID/Investigator# 28259
Kaletra in Combination With Integrase Inhibitors
Hamburg : Boehringer Ingelheim Investigational Site 24
Non-interventional Observational Study With Viramune in HIV to Evaluate Gender Specific Data
Hamburg : Boehringer Ingelheim Investigational Site 6
Non-interventional Observational Study With Viramune in HIV to Evaluate Gender Specific Data
Hamburg :
Occupational Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r) (PEPDar)
Hamburg : 1220.19.4919 Boehringer Ingelheim Investigational Site
Phase III Trial of BI 201335 in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)- Human Immunodeficiency Virus (HIV) Coinfected Patients
Hamburg : 1220.19.4920 Boehringer Ingelheim Investigational Site
Phase III Trial of BI 201335 in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)- Human Immunodeficiency Virus (HIV) Coinfected Patients
Hamburg : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Hamburg : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Hamburg : ICH Study Center
Strategic Timing of Antiretroviral Treatment
Hamburg : Ifi - Studien und Projekte GmbH
Strategic Timing of Antiretroviral Treatment
Hamburg : University Medical Centre Hamburg-Eppendorf
Strategic Timing of Antiretroviral Treatment
Hamburg : Local Institution
Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting
Hamburg : Site Reference ID/Investigator# 29272
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Hamburg : Site Reference ID/Investigator# 28566
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Hamburg : Site Reference ID/Investigator# 29267
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Hamburg : Site Reference ID/Investigator# 32386
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Hamburg : Site Reference ID/Investigator# 28544
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Hamburg : Site Reference ID/Investigator# 28513
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Hamburg : Site Reference ID/Investigator# 28507
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Hamburg : Site Reference ID/Investigator# 28489
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Hamburg : Site Reference ID/Investigator# 28515
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Hamburg : Site Reference ID/Investigator# 29261
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Hamburg : Site Reference ID/Investigator# 28549
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Hamburg : Site Reference ID/Investigator# 32382
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Hannover :
A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment
Hannover : Site Reference ID/Investigator# 28248
Kaletra in Combination With Integrase Inhibitors
Hannover : Site Reference ID/Investigator# 28230
Kaletra in Combination With Integrase Inhibitors
Hannover : Boehringer Ingelheim Investigational Site 17
Non-interventional Observational Study With Viramune in HIV to Evaluate Gender Specific Data
Hannover : Boehringer Ingelheim Investigational Site 12
Non-interventional Observational Study With Viramune in HIV to Evaluate Gender Specific Data
Hannover : Local Institution
Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting
Hannover : Site Reference ID/Investigator# 28568
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Hannover : Site Reference ID/Investigator# 29273
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Hannover : Site Reference ID/Investigator# 28523
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Hanover : Medizinische Hochschule Hannover
Strategic Timing of Antiretroviral Treatment
Heidelberg : Universitaetsklinikum Heidelberg
Strategic Timing of Antiretroviral Treatment
Heidelberg : Site Reference ID/Investigator# 47145
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Karlsruhe : Boehringer Ingelheim Investigational Site 37
Non-interventional Observational Study With Viramune in HIV to Evaluate Gender Specific Data
Karlsruhe : Site Reference ID/Investigator# 28551
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Koblenz : Site Reference ID/Investigator# 47153
Kaletra in Combination With Integrase Inhibitors
Koblenz : Boehringer Ingelheim Investigational Site 16
Non-interventional Observational Study With Viramune in HIV to Evaluate Gender Specific Data
Koblenz : Site Reference ID/Investigator# 28561
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Koeln : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Koln : Klinik I fur Innere Medizin der Universitat zu Koeln, Studienbuero fuer Infektiologie u. HIV CRS
Strategic Timing of Antiretroviral Treatment
Köln :
A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment
Köln : Boehringer Ingelheim Investigational Site 27
Non-interventional Observational Study With Viramune in HIV to Evaluate Gender Specific Data
Köln :
Occupational Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r) (PEPDar)
Krefeld : Site Reference ID/Investigator# 18221
Kaletra in Combination With Integrase Inhibitors
Krefeld : Site Reference ID/Investigator# 28483
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Leipzig : Boehringer Ingelheim Investigational Site 23
Non-interventional Observational Study With Viramune in HIV to Evaluate Gender Specific Data
Leipzig : Site Reference ID/Investigator# 47144
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Leipzig : Site Reference ID/Investigator# 28482
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Ludwigshafen : Site Reference ID/Investigator# 47151
Kaletra in Combination With Integrase Inhibitors
Ludwigshafen : Site Reference ID/Investigator# 28493
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Luebeck : Site Ref # / Investigator 28192
Kaletra in Combination With Integrase Inhibitors
Luebeck : Site Reference ID/Investigator# 28500
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Madgeburg : Site Reference ID/Investigator# 59468
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Magdeburg : Site Ref # / Investigator 54278
Kaletra in Combination With Integrase Inhibitors
Mainz :
Occupational Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r) (PEPDar)
Mainz : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Mainz : Site Reference ID/Investigator# 28574
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Mainz : Site Reference ID/Investigator# 28565
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Mannheim :
Occupational Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r) (PEPDar)
Mannheim : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Muenchen : GSK Investigational Site
Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine
Muenchen : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Muenster : Site Reference ID/Investigator# 28197
Kaletra in Combination With Integrase Inhibitors
Muenster : Site Reference ID/Investigator# 28492
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Muenster : Site Reference ID/Investigator# 28560
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Muenster : Site Reference ID/Investigator# 28490
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Munchen : Local Institution
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
Munchen : Klinikum der Universitaet Muenchen, Medizinische Poliklinik, Campus Innenstadt, Infektionsambulanz
Strategic Timing of Antiretroviral Treatment
Munchen : Local Institution
Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting
München : Boehringer Ingelheim Investigational Site 22
Non-interventional Observational Study With Viramune in HIV to Evaluate Gender Specific Data
München : Boehringer Ingelheim Investigational Site 29
Non-interventional Observational Study With Viramune in HIV to Evaluate Gender Specific Data
München : Boehringer Ingelheim Investigational Site 15
Non-interventional Observational Study With Viramune in HIV to Evaluate Gender Specific Data
München : Boehringer Ingelheim Investigational Site 7
Non-interventional Observational Study With Viramune in HIV to Evaluate Gender Specific Data
München : Boehringer Ingelheim Investigational Site 26
Non-interventional Observational Study With Viramune in HIV to Evaluate Gender Specific Data
München : Boehringer Ingelheim Investigational Site 33
Non-interventional Observational Study With Viramune in HIV to Evaluate Gender Specific Data
München : Boehringer Ingelheim Investigational Site 3
Non-interventional Observational Study With Viramune in HIV to Evaluate Gender Specific Data
München :
Occupational Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r) (PEPDar)
München : University München
Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.
München : 1220.19.4905 Boehringer Ingelheim Investigational Site
Phase III Trial of BI 201335 in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)- Human Immunodeficiency Virus (HIV) Coinfected Patients
München : 1220.19.4922 Boehringer Ingelheim Investigational Site
Phase III Trial of BI 201335 in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)- Human Immunodeficiency Virus (HIV) Coinfected Patients
Munich : Site Reference ID/Investigator# 28225
Kaletra in Combination With Integrase Inhibitors
Munich : Site Reference ID/Investigator# 28235
Kaletra in Combination With Integrase Inhibitors
Munich : Site Reference ID/Investigator# 28242
Kaletra in Combination With Integrase Inhibitors
Munich : Site Reference ID/Investigator# 28200
Kaletra in Combination With Integrase Inhibitors
Munich : Site Reference ID/Investigator# 28508
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Munich : Site Reference ID/Investigator# 28517
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Munich : Site Reference ID/Investigator# 28505
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Munich : Site Reference ID/Investigator# 28519
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Munich : Site Reference ID/Investigator# 28548
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Munich : Site Reference ID/Investigator# 28556
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Münster : Boehringer Ingelheim Investigational Site 13
Non-interventional Observational Study With Viramune in HIV to Evaluate Gender Specific Data
Oldenburg : Site Reference ID/Investigator# 28555
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Osnabrück : Boehringer Ingelheim Investigational Site 20
Non-interventional Observational Study With Viramune in HIV to Evaluate Gender Specific Data
Osnabrueck : Site Reference ID/Investigator# 28240
Kaletra in Combination With Integrase Inhibitors
Osnabrueck : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Osnabrueck : Site Reference ID/Investigator# 28553
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Regensburg : Site Reference ID/Investigator# 47149
Kaletra in Combination With Integrase Inhibitors
Regensburg :
Occupational Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r) (PEPDar)
Regensburg : University Clinic Regensburg, Klinik I Fuer Innere Medizin
Strategic Timing of Antiretroviral Treatment
Regensburg : Local Institution
Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting
Rostok : Site Reference ID/Investigator# 59467
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Saarbruecken : Site Reference ID/Investigator# 28506
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Schkeuditz : Site Reference ID/Investigator# 59471
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Stuttgart : Site Reference ID/Investigator# 28239
Kaletra in Combination With Integrase Inhibitors
Stuttgart : Site Reference ID/Investigator# 28257
Kaletra in Combination With Integrase Inhibitors
Stuttgart : Boehringer Ingelheim Investigational Site 35
Non-interventional Observational Study With Viramune in HIV to Evaluate Gender Specific Data
Stuttgart : Boehringer Ingelheim Investigational Site 40
Non-interventional Observational Study With Viramune in HIV to Evaluate Gender Specific Data
Stuttgart : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Stuttgart : Local Institution
Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting
Stuttgart : Site Reference ID/Investigator# 29265
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Stuttgart : Site Reference ID/Investigator# 28552
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Stuttgart :
Telaprevir Open-Label Study in Co-Infected Patients
Troisdorf : Site Reference ID/Investigator# 28572
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Tuebingen : Site Reference ID/Investigator# 28511
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Ulm :
Occupational Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r) (PEPDar)
Wiesbaden : Site Reference ID/Investigator# 29264
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Wuerzburg : University of Wuerzburg, Medizinische Poliklinik, Schwerpunkt Hepatologie/Infektologie CRS
Strategic Timing of Antiretroviral Treatment
Wuppertal : Site Reference ID/Investigator# 28546
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Würzburg : 1220.19.4923 Boehringer Ingelheim Investigational Site
Phase III Trial of BI 201335 in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)- Human Immunodeficiency Virus (HIV) Coinfected Patients
Greece
Athens : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Athens : Syngros Hospital
Strategic Timing of Antiretroviral Treatment
Athens : Korgialenio-Benakio Hellenic Red Cross
Strategic Timing of Antiretroviral Treatment
Athens : Evangelismos General Hospital
Strategic Timing of Antiretroviral Treatment
Athens : Hippokration University General Hospital of Athens
Strategic Timing of Antiretroviral Treatment
View More »
Athens : Attikon University General Hospital
Strategic Timing of Antiretroviral Treatment
Patras : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Piraeus : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Thessalonica : AHEPA University Hospital
Strategic Timing of Antiretroviral Treatment
Guatemala
Guatemala :
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Etravirine Administered in Combination With Other Antiretroviral Agents in Antiretroviral Treatment-Experienced HIV-1 Infected Patients
Hungary
Budapest :
A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment
India
Ahemdabad : Infectious Disease Clinic
Pregabalin Trial In HIV Neuropathic Pain
Chennai : GSK Investigational Site
Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females
Chennai :
TMC114-TiDP29-C232 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir (Rtv) for Children Coming From Any of the Three Ongoing Tibotec Sponsored Pediatric Studies With DRV
Hyderabad : Surakshaka Multispeciality Hospital
Pregabalin Trial In HIV Neuropathic Pain
Kolkata : GSK Investigational Site
Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females
View More »
Mangalore :
TMC278-TiDP38-C213 (PAINT): An Open Label Trial to Evaluate the Pharmacokinetics, Safety, Tolerability and Antiviral Efficacy of TMC278 in Antiretroviral Naive HIV-1 Infected Adolescents
Mumbai : GSK Investigational Site
Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females
Pune : GSK Investigational Site
Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females
Pune : Deenanath Mangeshkar Hospital and Research Centre
Pregabalin Trial In HIV Neuropathic Pain
Tharamani Chennai : GSK Investigational Site
Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Human Immunodeficiency Virus (HIV)-Positive Adults
Ireland
Dublin :
A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment
Dublin : Mater Hospital and UCD
Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.
Dublin : St James's Hospital Dublin
Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.
Dublin : Mater Misericordiae University Hospital
Strategic Timing of Antiretroviral Treatment
Dublin 9 :
A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment
View More »
Galway :
A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment
Israel
Beer-Sheva : Site Reference ID/Investigator# 27833
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Haifa : Rambam Medical Center
Strategic Timing of Antiretroviral Treatment
Haifa : Site Reference ID/Investigator# 17549
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Jerusalem : Site Reference ID/Investigator# 27830
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Kfar Saba : Site Reference ID/Investigator# 27832
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
View More »
Rehovot : Site Reference ID/Investigator# 27829
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Tel-Hashomer : Site Reference ID/Investigator# 27831
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Italy
Antella (fi) : 1220.19.3901 Boehringer Ingelheim Investigational Site
Phase III Trial of BI 201335 in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)- Human Immunodeficiency Virus (HIV) Coinfected Patients
Bagno a Ripoli (FI) : GSK Investigational Site
A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
Bari : 1220.19.3902 Boehringer Ingelheim Investigational Site
Phase III Trial of BI 201335 in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)- Human Immunodeficiency Virus (HIV) Coinfected Patients
Bari : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Bergamo : GSK Investigational Site
A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
View More »
Bologna : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Brescia : 1220.19.3906 Boehringer Ingelheim Investigational Site
Phase III Trial of BI 201335 in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)- Human Immunodeficiency Virus (HIV) Coinfected Patients
Brescia : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Busto Arsizio (Va) : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Firenze : GSK Investigational Site
A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
Firenze : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Florence : Italian Register for HIV-infection in Children
Post-marketing Safety Surveillance Program in Human Immunodeficiency Virus (HIV)-Infected Children Exposed to Atazanavir in Europe
Genova : GSK Investigational Site
A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
Genova : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Milan : Infectious Diseases Department Fondazione Centro San Raffaele
Efficacy of Atazanavir/Ritonavir Monotherapy as Maintenance in Patients With Viral Suppression
Milan : San Raffaele Hospital Dep. Infectious Diseases
Lopinavir/Ritonavir Monotherapy Versus Standard Highly Active Antiretroviral Therapy (HAART) in HIV/HCV Coinfected Antiretroviral (ARV) Naive Patients Starting Treatment With Anti-HCV Therapy
Milan : San Raffaele Hospital, Dep. Infectious Diseases
Lopinavir/Ritonavir Monotherapy Versus Standard Highly Active Antiretroviral Therapy (HAART) in HIV/HCV Coinfected Patients Starting Treatment With Anti-Hepatitis C Virus (HCV) Therapy
Milano : GSK Investigational Site
A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
Milano : 1220.19.3907 Boehringer Ingelheim Investigational Site
Phase III Trial of BI 201335 in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)- Human Immunodeficiency Virus (HIV) Coinfected Patients
Milano : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Milano : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Milano : Ospedale San Raffaele
Strategic Timing of Antiretroviral Treatment
Modena : Policlinico di Modena, Divisione di Malattie Infettive
A Phase I Safety and Immunogenicity Preventive Vaccine Trial Based on the HIV-1 Tat and V2-deleted Env Proteins (ISS P-002)
Modena : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Modena : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Monza : Azienda Ospedaliera San Gerardo, Divisione di Malattie Infettive
A Phase I Safety and Immunogenicity Preventive Vaccine Trial Based on the HIV-1 Tat and V2-deleted Env Proteins (ISS P-002)
Napoli : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Padova : Pfizer Investigational Site
An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children
Palermo : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Pavia : 1220.19.3905 Boehringer Ingelheim Investigational Site
Phase III Trial of BI 201335 in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)- Human Immunodeficiency Virus (HIV) Coinfected Patients
Pavia : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Pescara : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Roma : Pfizer Investigational Site
An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children
Roma : 1220.19.3903 Boehringer Ingelheim Investigational Site
Phase III Trial of BI 201335 in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)- Human Immunodeficiency Virus (HIV) Coinfected Patients
Roma : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Rome : IFO - S. Gallicano, Dermatologia Infettiva
A Phase I Safety and Immunogenicity Preventive Vaccine Trial Based on the HIV-1 Tat and V2-deleted Env Proteins (ISS P-002)
Rome : IRCSS
Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.
Rome : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Torino : GSK Investigational Site
A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
Torino : 1220.19.3904 Boehringer Ingelheim Investigational Site
Phase III Trial of BI 201335 in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)- Human Immunodeficiency Virus (HIV) Coinfected Patients
Torino : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Torino : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Varese : Ospedale di Circolo and Fondazione Macchi
Coadministration of Ezetimibe With Fenofibrate Versus Pravastatin Monotherapy for the Treatment of Hyperlipidaemia in HIV-infected Patients
Japan
Aichi : Site Ref # / Investigator 57626
Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infection
Aichi : Site Ref # / Investigator 57625
Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infection
Fukuoka : Site Ref # / Investigator 57628
Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infection
Fukuoka : Site Ref # / Investigator 57629
Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infection
Hiroshima : Site Ref # / Investigator 57630
Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infection
View More »
Hokkaido : Site Ref # / Investigator 57631
Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infection
Hyogo : Site Ref # / Investigator 57632
Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infection
Kanagawa : Site Ref # / Investigator 57633
Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infection
Kyoto : Site Ref # / Investigator 57634
Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infection
Miyagi : Site Ref # / Investigator 57636
Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infection
Niigata : Site Ref # / Investigator 57637
Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infection
Okayama : Site Ref # / Investigator 57638
Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infection
Osaka : Site Ref # / Investigator 57639
Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infection
Tokyo : Site Ref # / Investigator 57641
Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infection
Tokyo : Site Ref # / Investigator 57647
Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infection
Tokyo : Site Ref # / Investigator 57651
Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infection
Tokyo : Site Ref # / Investigator 57644
Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infection
Tokyo : Site Ref # / Investigator 57645
Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infection
Tokyo : Site Ref # / Investigator 57650
Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infection
Tokyo : Site Ref # / Investigator 48722
Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infection
Korea, Republic of
Incheon : GSK Investigational Site
ZIAGEN® Post-marketing Surveillance
Seoul : Seoul National University Hospital
Gene Therapy With GX-12 in Combination With HAART for the HIV-1 Infected Patients
Seoul : MSD Korea Ltd.
Stocrin Re-examination Study (0831-028 AM1)
Luxembourg
Luxembourg : Centre Hospitalier de Luxembourg
Strategic Timing of Antiretroviral Treatment
Malawi
Blantyre : College of Med. JHU CRS
Study of Effects of Tenofovir on Bone Health and Kidneys During Pregnancy and Breastfeeding
Lilongwe : University of North Carolina Lilongwe CRS
Study of Effects of Tenofovir on Bone Health and Kidneys During Pregnancy and Breastfeeding
Mali
Bamako : Serefo/Cesac Mali
Strategic Timing of Antiretroviral Treatment
Mexico
Distrito Federal : Local Institution
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
Guadalajara : Hospital Civil de Guadalajara "Fray Antonio Alcalde"
Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment
Guadalajara : Local Institution
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
Guadalajara : Local Institution
Phase IIIB Pediatric ATV Powder for Oral Use (POU) (PRINCE2)
Merida : Local Institution
Phase IIIB Pediatric ATV Powder for Oral Use (POU) (PRINCE2)
View More »
Mexico : Pfizer Investigational Site
An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children
Oaxaca : Local Institution
Phase IIIB Pediatric ATV Powder for Oral Use (POU) (PRINCE2)
Morocco
Netherlands
Amsterdam : Academic Medical Center
Mycophenolate Mofetil in Antiretroviral Naïve Patients 2 (MAN2 Study)
Nijmegen : Radboud University Nijmegen Medical Centre
Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.
Rotterdam : Erasmus Medical Center
Mycophenolate Mofetil in Antiretroviral Naïve Patients 2 (MAN2 Study)
Rotterdam : Erasmus Medical Center Rotterdam
Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.
Utrecht : University Medical Center Utrecht
RAltegravir Switch STudy: Effects on Endothelial Recovery
Nigeria
Norway
Oslo : Oslo University Hospital, Ulleval
Strategic Timing of Antiretroviral Treatment
Peru
Barranco : Local Institution
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
Cercado : Local Institution
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
Iquitos : Local Institution
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
Jesus Maria : Local Institution
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
La Victoria : Local Institution
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
View More »
Lima : Asociacion Civil Impacta Salud y Educacion
Strategic Timing of Antiretroviral Treatment
Lima : IMPACTA San Miguel
Strategic Timing of Antiretroviral Treatment
Lima : Hospital Nacional Edgardo Rebagliati Martins
Strategic Timing of Antiretroviral Treatment
Lima : Hospital Nacional Guillermo Almenara Irigoyen
Strategic Timing of Antiretroviral Treatment
Lima : Via Libre
Strategic Timing of Antiretroviral Treatment
San Miguel : Local Institution
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
Poland
Bia?ystok : Boehringer Ingelheim Investigational Site 7
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Bialystok :
Observational Study on Predictors of Response to Invirase (Saquinavir) Treatment in Treatment-naïve Patients With HIV Infection
Bialystok : Wojewodzki Szpital Specjalistyczny
Strategic Timing of Antiretroviral Treatment
Bydgoszcz : Boehringer Ingelheim Investigational Site 8
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Bydgoszcz :
Observational Study on Predictors of Response to Invirase (Saquinavir) Treatment in Treatment-naïve Patients With HIV Infection
View More »
Chorzow :
Observational Study on Predictors of Response to Invirase (Saquinavir) Treatment in Treatment-naïve Patients With HIV Infection
Chorzów : Boehringer Ingelheim Investigational Site 9
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Gda?sk : Boehringer Ingelheim Investigational Site 10
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Kraków : Boehringer Ingelheim Investigational Site 11
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Lodz :
Observational Study on Predictors of Response to Invirase (Saquinavir) Treatment in Treatment-naïve Patients With HIV Infection
Pozna? : Boehringer Ingelheim Investigational Site 12
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Szczecin : Boehringer Ingelheim Investigational Site 13
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Warsaw : Wojewodzki Szpital Zakazny
Strategic Timing of Antiretroviral Treatment
Warszawa : Boehringer Ingelheim Investigational Site 14
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Warszawa : Boehringer Ingelheim Investigational Site 15
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Warszawa :
Observational Study on Predictors of Response to Invirase (Saquinavir) Treatment in Treatment-naïve Patients With HIV Infection
Warszawa : Local Institution
Phase IIIB Pediatric ATV Powder for Oral Use (POU) (PRINCE2)
Wroc?aw : Boehringer Ingelheim Investigational Site 16
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Wroclaw :
Observational Study on Predictors of Response to Invirase (Saquinavir) Treatment in Treatment-naïve Patients With HIV Infection
Wroclaw : EMC Instytut Medyczny SA
Strategic Timing of Antiretroviral Treatment
Portugal
Amadora : GSK Investigational Site
A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
Aveiro : Local Institution
Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting
Coimbra : GSK Investigational Site
A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
Faro : Pfizer Investigational Site
An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children
Lisboa : GSK Investigational Site
A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
View More »
Lisboa : Pfizer Investigational Site
An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children
Lisboa : Hospital de Santa Maria
Strategic Timing of Antiretroviral Treatment
Lisbon : Hospital Curry Cabral
Strategic Timing of Antiretroviral Treatment
Lisbon : Hospital de Egas Moniz
Strategic Timing of Antiretroviral Treatment
Porto : Pfizer Investigational Site
An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children
Porto : Hospital Joaquim Urbano
Strategic Timing of Antiretroviral Treatment
Puerto Rico
Ponce : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Rio Piedras : Pfizer Investigational Site
An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children
Rio Piedras : Local Institution
Phase IIIB Pediatric ATV Powder for Oral Use (POU) (PRINCE2)
Rio Piedras : RCMI-Clinical Research Center
Pregabalin Trial In HIV Neuropathic Pain
Rio Piedras : San Juan Hospital
Strategic Timing of Antiretroviral Treatment
View More »
San Juan :
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Etravirine Administered in Combination With Other Antiretroviral Agents in Antiretroviral Treatment-Experienced HIV-1 Infected Patients
San Juan : Puerto Rico
A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)
San Juan : San Juan City Hosp. PR NICHD CRS (5031) Updated
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
San Juan : Puerto Rico-AIDS CRS (5401)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
San Juan : HOPE Clinical Research
Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment
San Juan : Clinical Research Puerto Rico
Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment
San Juan : Fundacion de Investigacion de Diego
Drug Interaction Study of PSI-7977 and Antiretroviral Therapy(ART) Combinations in Human Immunodeficiency Virus and Hepatitis C Virus (HIV/HCV) Co-infected Patients.
San Juan : Univ. of Puerto Rico - ACTU
Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus
San Juan : University of Puerto Rico, School of Medicine, CEMI
Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus
San Juan : Clinical Research Puerto Rico Inc
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
San Juan : Clinical Research Puerto Rico
Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults
San Juan : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
San Juan : Puerto Rico-AIDS Clinical Trials Unit (PR-ACTU)
Strategic Timing of Antiretroviral Treatment
San Juan : University of Puerto Rico Pediatric Research Site
Strategic Timing of Antiretroviral Treatment
San Juan : Clinical Research Puert Rico
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
San Juan Pr : Updated
A Study to Assess the Pharmacokinetics (Blood Levels) of TMC114 (Darunavir) Taken With Ritonavir and/or TMC125 (Etravirine) and TMC278 (Rilpivirine) in HIV-1 Infected Pregnant Women
Santurce : Clinical Research P.R., Inc.
Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus
Santurce : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Romania
Brasov : Boehringer Ingelheim Investigational Site 48
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Brasov : Boehringer Ingelheim Investigational Site 49
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Brasov : Boehringer Ingelheim Investigational Site 50
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Bucharest : Victor Babes Hospital
Post-marketing Safety Surveillance Program in Human Immunodeficiency Virus (HIV)-Infected Children Exposed to Atazanavir in Europe
Bucuresti : Local Institution
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
View More »
Bucuresti : Boehringer Ingelheim Investigational Site 30
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Bucuresti : Boehringer Ingelheim Investigational Site 31
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Bucuresti : Boehringer Ingelheim Investigational Site 32
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Bucuresti : Boehringer Ingelheim Investigational Site 34
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Bucuresti : Boehringer Ingelheim Investigational Site 35
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Bucuresti : Boehringer Ingelheim Investigational Site 21
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Bucuresti : Boehringer Ingelheim Investigational Site 22
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Bucuresti : Boehringer Ingelheim Investigational Site 23
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Bucuresti : Boehringer Ingelheim Investigational Site 25
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Bucuresti : Boehringer Ingelheim Investigational Site 28
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Bucuresti : Boehringer Ingelheim Investigational Site 29
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Bucuresti : Boehringer Ingelheim Investigational Site 18
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Bucuresti : Boehringer Ingelheim Investigational Site 17
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Bucuresti : Boehringer Ingelheim Investigational Site 19
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Bucuresti : Boehringer Ingelheim Investigational Site 20
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Bucuresti : Boehringer Ingelheim Investigational Site 24
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Bucuresti : Boehringer Ingelheim Investigational Site 26
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Bucuresti : Boehringer Ingelheim Investigational Site 27
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Bucuresti : Boehringer Ingelheim Investigational Site 33
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Constanta : Local Institution
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
Constanta : Boehringer Ingelheim Investigational Site 40
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Constanta : Boehringer Ingelheim Investigational Site 41
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Constanta : Boehringer Ingelheim Investigational Site 42
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Constanta : Boehringer Ingelheim Investigational Site 43
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Craiova :
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Etravirine Administered in Combination With Other Antiretroviral Agents in Antiretroviral Treatment-Experienced HIV-1 Infected Patients
Craiova : Local Institution
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
Craiova : Boehringer Ingelheim Investigational Site 38
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Craiova : Boehringer Ingelheim Investigational Site 39
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Iasi : Local Institution
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
Iasi : Boehringer Ingelheim Investigational Site 44
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Iasi : Boehringer Ingelheim Investigational Site 45
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Iasi : Boehringer Ingelheim Investigational Site 46
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Iasi : Boehringer Ingelheim Investigational Site 47
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Tg.Mures : Boehringer Ingelheim Investigational Site 51
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Tg.Mures : Boehringer Ingelheim Investigational Site 52
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Tg.Mures : Boehringer Ingelheim Investigational Site 53
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Tg.Mures : Boehringer Ingelheim Investigational Site 54
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Timisoara : Boehringer Ingelheim Investigational Site 36
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Timisoara : Boehringer Ingelheim Investigational Site 37
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Russian Federation
Krasnodar :
A Trial With TMC278-TIDP6-C222 for Continued TMC278 Access in Patients Infected With Human Immunodeficiency Virus-1
Moscow : Central Research Institute of Epidemiology
Raltegravir + Lamivudine/Abacavir in HIV/Tuberculosis Co-Infected Patients
Moscow N/A :
A Trial With TMC278-TIDP6-C222 for Continued TMC278 Access in Patients Infected With Human Immunodeficiency Virus-1
Smolensk :
A Trial With TMC278-TIDP6-C222 for Continued TMC278 Access in Patients Infected With Human Immunodeficiency Virus-1
Smolensk : Local Institution
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
View More »
Smolensk : Local Institution
Phase IIIB Pediatric ATV Powder for Oral Use (POU) (PRINCE2)
St Petersburg :
A Trial With TMC278-TIDP6-C222 for Continued TMC278 Access in Patients Infected With Human Immunodeficiency Virus-1
St. Petersburg : Local Institution
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
St. Petersburg : Local Institution
Phase IIIB Pediatric ATV Powder for Oral Use (POU) (PRINCE2)
St.Petersburg : Local Institution
Phase IIIB Pediatric ATV Powder for Oral Use (POU) (PRINCE2)
St-Petersburg : Local Institution
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
Volgograd :
A Trial With TMC278-TIDP6-C222 for Continued TMC278 Access in Patients Infected With Human Immunodeficiency Virus-1
Voronezh :
A Trial With TMC278-TIDP6-C222 for Continued TMC278 Access in Patients Infected With Human Immunodeficiency Virus-1
Senegal
Dakar : Clinical Research and Training Center, Fann Hospital
Evaluation of Three Strategies of Second-line Antiretroviral Treatment in Africa (Dakar - Bobo-Dioulasso - Yaoundé)
South Africa
Benoni : Pfizer Investigational Site
An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children
Benoni : Local Institution
Phase IIIB Pediatric ATV Powder for Oral Use (POU) (PRINCE2)
Benoni : Worthwhile Clinical Trials (WWCT), Lake View Hospital
Pregabalin Trial In HIV Neuropathic Pain
Bloemfontein :
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Etravirine Administered in Combination With Other Antiretroviral Agents in Antiretroviral Treatment-Experienced HIV-1 Infected Patients
Bloemfontein : Local Institution
Phase IIIB Pediatric ATV Powder for Oral Use (POU) (PRINCE2)
View More »
Bloemfontein :
TMC278-TiDP38-C213 (PAINT): An Open Label Trial to Evaluate the Pharmacokinetics, Safety, Tolerability and Antiviral Efficacy of TMC278 in Antiretroviral Naive HIV-1 Infected Adolescents
Cape Town : Local Institution
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
Cape Town : University of Cape Town
Pregabalin Trial In HIV Neuropathic Pain
Cape Town : Desmond Tutu HIV Foundation
Strategic Timing of Antiretroviral Treatment
Cape Town : Stellenbosch Univ. CRS
Study of Effects of Tenofovir on Bone Health and Kidneys During Pregnancy and Breastfeeding
Cape Town :
TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Children and Adolescents
Diepkloof : Perinatal HIV Research UNIT
Emtricitabine Given Once A Day With Other Anti-HIV Drugs in Children With HIV
Dundee : Local Institution
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
Dundee : Pfizer Investigational Site
Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in HIV-Infected Subjects 6 Years of Age or Older Who Are Naive to Pneumococcal Vaccine
Dundee :
TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Children and Adolescents
Dundee :
TMC278-TiDP38-C213 (PAINT): An Open Label Trial to Evaluate the Pharmacokinetics, Safety, Tolerability and Antiviral Efficacy of TMC278 in Antiretroviral Naive HIV-1 Infected Adolescents
Durban : Local Institution
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
Durban : Synapta Clinical Research Centre
Pregabalin Trial In HIV Neuropathic Pain
Durban :
TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Children and Adolescents
Durban Kwazulu Natal :
TMC114-TiDP29-C232 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir (Rtv) for Children Coming From Any of the Three Ongoing Tibotec Sponsored Pediatric Studies With DRV
Gaunteng : Infectious Diseases Clinincal Trial Unit
Emtricitabine Given Once A Day With Other Anti-HIV Drugs in Children With HIV
Johannesburg : Local Institution
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
Johannesburg : Drs Essack and Mitha
Pregabalin Trial In HIV Neuropathic Pain
Johannesburg : Toga Laboratory
Pregabalin Trial In HIV Neuropathic Pain
Johannesburg : CHRU
Strategic Timing of Antiretroviral Treatment
Johannesburg : Shandukani Research CRS
Study of Effects of Tenofovir on Bone Health and Kidneys During Pregnancy and Breastfeeding
Johannesburg :
TMC114-TiDP29-C232 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir (Rtv) for Children Coming From Any of the Three Ongoing Tibotec Sponsored Pediatric Studies With DRV
Johannesburg, Gauteng : Soweto IMPAACT CRS
Study of Effects of Tenofovir on Bone Health and Kidneys During Pregnancy and Breastfeeding
Klerksdorp : Aurum Institute
Safety and Immunogenicity of AERAS-402 in HIV-infected, Bacillus Calmette-Guerin (BCG)-Vaccinated Adults
Newtown :
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Etravirine Administered in Combination With Other Antiretroviral Agents in Antiretroviral Treatment-Experienced HIV-1 Infected Patients
Paarl : Be Part Yoluntu Centre
Pregabalin Trial In HIV Neuropathic Pain
Paarl : Paarl Research Center
Pregabalin Trial In HIV Neuropathic Pain
Parrow Valley : Local Institution
Phase IIIB Pediatric ATV Powder for Oral Use (POU) (PRINCE2)
Port Elizabeth :
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Etravirine Administered in Combination With Other Antiretroviral Agents in Antiretroviral Treatment-Experienced HIV-1 Infected Patients
Port Elizabeth : MediSynergy
Pregabalin Trial In HIV Neuropathic Pain
Pretoria :
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Etravirine Administered in Combination With Other Antiretroviral Agents in Antiretroviral Treatment-Experienced HIV-1 Infected Patients
Pretoria : Local Institution
Phase IIIB Pediatric ATV Powder for Oral Use (POU) (PRINCE2)
Pretoria :
TMC278-TiDP38-C213 (PAINT): An Open Label Trial to Evaluate the Pharmacokinetics, Safety, Tolerability and Antiviral Efficacy of TMC278 in Antiretroviral Naive HIV-1 Infected Adolescents
Pretoria N/A :
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Etravirine Administered in Combination With Other Antiretroviral Agents in Antiretroviral Treatment-Experienced HIV-1 Infected Patients
Pretoria West : Pretoria West Hospital
Pregabalin Trial In HIV Neuropathic Pain
Soweto : Local Institution
Phase IIIB Pediatric ATV Powder for Oral Use (POU) (PRINCE2)
Soweto : Pfizer Investigational Site
Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in HIV-Infected Subjects 6 Years of Age or Older Who Are Naive to Pneumococcal Vaccine
Stanger : Dr J. Reddy's Surgery
Pregabalin Trial In HIV Neuropathic Pain
Umlazi : CAPRISA Umlazi CRS
Study of Effects of Tenofovir on Bone Health and Kidneys During Pregnancy and Breastfeeding
Westdene Johannesburg Gauteng :
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Etravirine Administered in Combination With Other Antiretroviral Agents in Antiretroviral Treatment-Experienced HIV-1 Infected Patients
Worcester : Pfizer Investigational Site
Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in HIV-Infected Subjects 6 Years of Age or Older Who Are Naive to Pneumococcal Vaccine
Spain
A Coruña : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Alcala de Henares : Hospital Universitario Principe de Asturias
Strategic Timing of Antiretroviral Treatment
Alcalá de Henares : Hospital Príncipe de Asturias
HCV Evolution in HIV/HCV (Genotype 1) Coinfected Patients Treated With Fosamprenavir
Alcalá de Henares : Hospital Príncipe de Asturias
Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy
Alicante : GSK Investigational Site
A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
View More »
Alicante : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Alicante : Hospital General de Alicante
Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy
Badalona :
A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment
Badalona : GSK Investigational Site
A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
Badalona : Local Institution
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
Badalona : GSK Investigational Site
Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine
Badalona : Hospital Universitari Germans Trias i Pujol, Badalona
Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.
Badalona : 1220.19.3404 Boehringer Ingelheim Investigational Site
Phase III Trial of BI 201335 in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)- Human Immunodeficiency Virus (HIV) Coinfected Patients
Badalona : Hospital Universitari Germans Trias I Pujol, HIV Unit and Retrovirology Lab CRS
Strategic Timing of Antiretroviral Treatment
Badalona : Local Institution
Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting
Barcelona :
A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment
Barcelona : GSK Investigational Site
A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
Barcelona : Barcelona
A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)
Barcelona : Local Institution
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
Barcelona : GSK Investigational Site
Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine
Barcelona : 1220.19.3401 Boehringer Ingelheim Investigational Site
Phase III Trial of BI 201335 in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)- Human Immunodeficiency Virus (HIV) Coinfected Patients
Barcelona : 1220.19.3403 Boehringer Ingelheim Investigational Site
Phase III Trial of BI 201335 in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)- Human Immunodeficiency Virus (HIV) Coinfected Patients
Barcelona : Local Institution
Phase IIIB Pediatric ATV Powder for Oral Use (POU) (PRINCE2)
Barcelona : Spanish Perinatal Cohort
Post-marketing Safety Surveillance Program in Human Immunodeficiency Virus (HIV)-Infected Children Exposed to Atazanavir in Europe
Barcelona : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Barcelona : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Barcelona : Hospital Vall d'Hebrón
Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy
Barcelona : Hospital Santa Creu i Sant Pau
Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy
Barcelona : Hospital del Mar
Strategic Timing of Antiretroviral Treatment
Barcelona : Hospital de la Santa Creu i Sant Pau
Strategic Timing of Antiretroviral Treatment
Barcelona : Hospital Clinico de Barcelona CRS
Strategic Timing of Antiretroviral Treatment
Barcelona : Local Institution
Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting
Basurto : Hospital de Basurto
Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy
Cadiz : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Cordoba : Local Institution
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
Cordoba : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Cordoba : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Córdoba : Hospital Reina Sofía
Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy
El Ferrol : Hospital Arquitecto Marcide
Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy
Elche : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Elche : Hospital de Elche
Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy
Esplugues de Llobregat : Pfizer Investigational Site
An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children
Esplugues De Llobregat :
TMC114-TiDP29-C232 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir (Rtv) for Children Coming From Any of the Three Ongoing Tibotec Sponsored Pediatric Studies With DRV
Granada : Hospital Universitario Virgen de las Nieves Granada; Médico Adjunto del Servicio de Medicina Interna
Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.
Granada : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Granada : Hospital Clínico San Cecilio
Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy
Granada : Hospital Virgen de las Nieves
Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy
Granada : Local Institution
Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting
Granollers : Hospital General de Granollers
Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy
Guadalajara : Local Institution
Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting
Jerez de la Frontera : Hospital de Jerez
Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy
La Coruña : GSK Investigational Site
A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
La Coruña : Hospital Juan Canalejo
Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy
Leganes : Local Institution
Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting
Leganés : Hospital Severo Ochoa
Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy
L'Hospitalet de Llobregat : 1220.19.3402 Boehringer Ingelheim Investigational Site
Phase III Trial of BI 201335 in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)- Human Immunodeficiency Virus (HIV) Coinfected Patients
Logrono : Local Institution
Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting
Logroño : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Madrid : GSK Investigational Site
A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
Madrid : Pfizer Investigational Site
An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children
Madrid : Hospital Clínico San Carlos
HCV Evolution in HIV/HCV (Genotype 1) Coinfected Patients Treated With Fosamprenavir
Madrid : Hospital La Paz
HCV Evolution in HIV/HCV (Genotype 1) Coinfected Patients Treated With Fosamprenavir
Madrid : Hospital Doce de Octubre
HCV Evolution in HIV/HCV (Genotype 1) Coinfected Patients Treated With Fosamprenavir
Madrid : Hospital Gregorio Marañón
HCV Evolution in HIV/HCV (Genotype 1) Coinfected Patients Treated With Fosamprenavir
Madrid : Hospital Ramón y Cajal
HCV Evolution in HIV/HCV (Genotype 1) Coinfected Patients Treated With Fosamprenavir
Madrid : Local Institution
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
Madrid : GSK Investigational Site
Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine
Madrid : 1220.19.3405 Boehringer Ingelheim Investigational Site
Phase III Trial of BI 201335 in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)- Human Immunodeficiency Virus (HIV) Coinfected Patients
Madrid : 1220.19.3406 Boehringer Ingelheim Investigational Site
Phase III Trial of BI 201335 in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)- Human Immunodeficiency Virus (HIV) Coinfected Patients
Madrid : 1220.19.3407 Boehringer Ingelheim Investigational Site
Phase III Trial of BI 201335 in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)- Human Immunodeficiency Virus (HIV) Coinfected Patients
Madrid : Local Institution
Phase IIIB Pediatric ATV Powder for Oral Use (POU) (PRINCE2)
Madrid : Madrid Paediatric HIV Cohort
Post-marketing Safety Surveillance Program in Human Immunodeficiency Virus (HIV)-Infected Children Exposed to Atazanavir in Europe
Madrid : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Madrid : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Madrid : Hospital Gregorio Marañón
Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy
Madrid : Hospital La Paz
Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy
Madrid : Hospital Ramón y Cajal
Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy
Madrid : Hospital Doce de Octubre
Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy
Madrid : Hospital Clinico San Carlos
Strategic Timing of Antiretroviral Treatment
Madrid : Hospital Carlos III
Strategic Timing of Antiretroviral Treatment
Madrid : Hospital Universitario Doce de Octubre
Strategic Timing of Antiretroviral Treatment
Madrid : Hospital La Paz CRS
Strategic Timing of Antiretroviral Treatment
Madrid : Hospital La Princesa, Internal Medicine and Infectious Disease Service CRS
Strategic Timing of Antiretroviral Treatment
Madrid : Local Institution
Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting
Madrid : Hospital La Paz
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Malaga : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Malaga : Local Institution
Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting
Málaga : Hospital Virgen de la Victoria
Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy
Marbella : Hospital Costa del Sol
Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy
Marbella : Local Institution
Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting
Mataro : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Mataro : Local Institution
Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting
Mataró : Hospital de Mataró
Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy
Mostoles : Local Institution
Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting
Mostoles, Madrid : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Móstoles, Madrid : GSK Investigational Site
Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine
Pamplona : Hospital de Navarra
Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy
San Sebastian : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
San Sebastián : Hospital Donostia
Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy
Santander : Hospital Marqués de Valdecilla
Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy
Santiago de Compostela : Complexo Hospitalario Universitario de Santiago
Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy
Santiago de Compostela : Local Institution
Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting
Sevilla : GSK Investigational Site
A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
Sevilla : 1220.19.3408 Boehringer Ingelheim Investigational Site
Phase III Trial of BI 201335 in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)- Human Immunodeficiency Virus (HIV) Coinfected Patients
Sevilla : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Sevilla : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Sevilla : Local Institution
Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting
Tarragona : Hospital de Santa Tecla
Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy
Tarragona : Local Institution
Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting
Tenerife, Canary Island : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Terrassa : Hospital Universitari Mutua Terrassa
Strategic Timing of Antiretroviral Treatment
Valencia : GSK Investigational Site
Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine
Valencia : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Valencia : Hospital La Fe
Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy
Valencia : Hospital General Universitario de Valencia
Strategic Timing of Antiretroviral Treatment
Valencia : Hospital Universitario y Politecnico La Fe
Strategic Timing of Antiretroviral Treatment
Valencia : Local Institution
Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting
Vigo : Hospital Xeral Cíes
Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy
Vigo : Complejo Hospitalario Xeral Cies
Strategic Timing of Antiretroviral Treatment
Villajoyosa : Hospital Marina Baixa
Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy
Sweden
Gothenburg : Sahlgrenska University Hospital
Strategic Timing of Antiretroviral Treatment
Malmo : Skane University Hospital
Strategic Timing of Antiretroviral Treatment
Stockholm :
A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment
Switzerland
Basel : University Hospital Basel
Cardiovascular Risk Factor Management in HIV Infection
Basel : 1220.19.4101 Boehringer Ingelheim Investigational Site
Phase III Trial of BI 201335 in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)- Human Immunodeficiency Virus (HIV) Coinfected Patients
Basel : Swiss Mother and Child HIV Cohort
Post-marketing Safety Surveillance Program in Human Immunodeficiency Virus (HIV)-Infected Children Exposed to Atazanavir in Europe
Basel : University Hospital Basel
Strategic Timing of Antiretroviral Treatment
Bern : 1220.19.4103 Boehringer Ingelheim Investigational Site
Phase III Trial of BI 201335 in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)- Human Immunodeficiency Virus (HIV) Coinfected Patients
View More »
Bern : Poliklinik fur Infektiologie
Strategic Timing of Antiretroviral Treatment
Berne : Klinik und Poliklinik für Infektiologie, Inselspital
Cardiovascular Risk Factor Management in HIV Infection
Geneva : Division des Maladies Infectieuses, Hopital Universitaire Geneve
Cardiovascular Risk Factor Management in HIV Infection
Geneva : HUG /Division des Maladies infectieuses Unité VIH/SIDA
Prospective Evaluation of Etravirine for HIV-infected Patients in Need of Lipid-lowering Drugs
Geneva : Unite VIH/SIDA Geneva
Strategic Timing of Antiretroviral Treatment
Lausanne : Division Maladies Infectieuses, Hopital Universitaire Vaudois (CHUV)
Cardiovascular Risk Factor Management in HIV Infection
Lausanne : CHUV / Service des maladies infectieuses Médecine 2
Prospective Evaluation of Etravirine for HIV-infected Patients in Need of Lipid-lowering Drugs
Lugano : Ospedale Civico Lugano
Cardiovascular Risk Factor Management in HIV Infection
Lugano : 1220.19.4102 Boehringer Ingelheim Investigational Site
Phase III Trial of BI 201335 in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)- Human Immunodeficiency Virus (HIV) Coinfected Patients
Lugano : Ospedale Civico di Lugano
Strategic Timing of Antiretroviral Treatment
St. Gallen : Departement Innere Medizin Kantonsspital St. Gallen
Cardiovascular Risk Factor Management in HIV Infection
Zurich : Abteilung für Infektionskrankheiten & Spitalhygiene, Universitätsspital Zürich
Cardiovascular Risk Factor Management in HIV Infection
Zurich : University Hospital Zurich
Raltegravir in the Swiss HIV Cohort Study
Zurich : University Hospital Zurich
Strategic Timing of Antiretroviral Treatment
Zürich : 1220.19.4104 Boehringer Ingelheim Investigational Site
Phase III Trial of BI 201335 in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)- Human Immunodeficiency Virus (HIV) Coinfected Patients
Tanzania
IDC Research Offices : Kilimanjaro Christian Medical CRS (12901) Updated
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Thailand
Bangkok : Bhumibol Adulyadej Hospital (8355) Updated
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Bangkok : Pfizer Investigational Site
An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children
Bangkok : Thai Red Cross AIDS Research Centre
Antiretroviral Therapy for Acute HIV Infection
Bangkok : GSK Investigational Site
Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females
Bangkok : Neurology unit, Department of Medicine,
Pregabalin Trial In HIV Neuropathic Pain
View More »
Bangkok : South East Asia Research Collaboration with Hawaii
Pregabalin Trial In HIV Neuropathic Pain
Bangkok : Ramathibodi Hospital
Strategic Timing of Antiretroviral Treatment
Bangkok : Chulalongkorn University Hospital
Strategic Timing of Antiretroviral Treatment
Bangkok :
TMC278-TiDP38-C213 (PAINT): An Open Label Trial to Evaluate the Pharmacokinetics, Safety, Tolerability and Antiviral Efficacy of TMC278 in Antiretroviral Naive HIV-1 Infected Adolescents
Bangkok noi : Pfizer Investigational Site
An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children
Bangkoknoi : Siriraj Hospital
Strategic Timing of Antiretroviral Treatment
Chantaburi : Prapokklao Hospital CRS (8354) Updated
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Chiang Mai : Chaing Mai University (20101) Updated
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Chiang Mai : Research Institute for Health Sciences (RIHES)
Strategic Timing of Antiretroviral Treatment
Chiang Mai : Sanpatong Hospital
Strategic Timing of Antiretroviral Treatment
Chiang Mai :
TMC114IFD3001 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir (Rtv) for Adults Coming From Any of the Three Ongoing Tibotec-Sponsored Studies With DRV
Chiang Rai : Chiang Rai Regional Hospital CRS (8352) Updated
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Chiangmai : GSK Investigational Site
Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females
Chiangrai : Chiangrai Prachanukroh Hospital
Strategic Timing of Antiretroviral Treatment
Chonburi : Chonburi Hosp. CRS (8356) Updated
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Chonburi : Chonburi Regional Hospital
Strategic Timing of Antiretroviral Treatment
Khon Kaen : Khon Kaen University, Srinagarind Hospital
Strategic Timing of Antiretroviral Treatment
Khon Kaen :
TMC278-TiDP38-C213 (PAINT): An Open Label Trial to Evaluate the Pharmacokinetics, Safety, Tolerability and Antiviral Efficacy of TMC278 in Antiretroviral Naive HIV-1 Infected Adolescents
Nonthaburi : Bamrasnaradura Institute
Strategic Timing of Antiretroviral Treatment
Phayao : Phayao Provincial Hospital CRS (8353) Updated
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Uganda
Entebbe : MRC UVRI Uganda Research Unit on AIDS
Strategic Timing of Antiretroviral Treatment
Kampala : Makerere University - JHU Research Collaboration (30293) Updated
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Kampala : Joint Clinical Research Center (JCRC)
Strategic Timing of Antiretroviral Treatment
Kampala : Makerere University- JHU Research Collaboration {MUJHU CARE LTD} CRS
Study of Effects of Tenofovir on Bone Health and Kidneys During Pregnancy and Breastfeeding
Kampala :
TMC278-TiDP38-C213 (PAINT): An Open Label Trial to Evaluate the Pharmacokinetics, Safety, Tolerability and Antiviral Efficacy of TMC278 in Antiretroviral Naive HIV-1 Infected Adolescents
Ukraine
Donetsk :
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Etravirine Administered in Combination With Other Antiretroviral Agents in Antiretroviral Treatment-Experienced HIV-1 Infected Patients
Kyiv :
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Etravirine Administered in Combination With Other Antiretroviral Agents in Antiretroviral Treatment-Experienced HIV-1 Infected Patients
Kyiv :
TMC114-TiDP29-C232 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir (Rtv) for Children Coming From Any of the Three Ongoing Tibotec Sponsored Pediatric Studies With DRV
United Kingdom
Belfast : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Belfast : Belfast Health and Social Care Trust (RVH)
Strategic Timing of Antiretroviral Treatment
Birmingham : Local Institution
Phase IIIB Pediatric ATV Powder for Oral Use (POU) (PRINCE2)
Birmingham : Birmingham Heartlands Hospital
Strategic Timing of Antiretroviral Treatment
Birmingham : Queen Elizabeth Hospital Birmingham
Strategic Timing of Antiretroviral Treatment
View More »
Birmingham : Heart of England NHS Foundation Trust
The CogNaive Study: Assessing Changes in Neurocognitive Function in Treatment Naïve HIV-1 Positive Subjects
Bournemouth : Royal Bournemouth Hospital
Strategic Timing of Antiretroviral Treatment
Brighton :
A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment
Brighton : Brighton and Sussex University Hospitals NHS Trust
Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment
Brighton : 1220.19.4406 Boehringer Ingelheim Investigational Site
Phase III Trial of BI 201335 in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)- Human Immunodeficiency Virus (HIV) Coinfected Patients
Brighton : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Brighton : Brighton and Sussex University Hospitals NHS Trust
Strategic Timing of Antiretroviral Treatment
Cottingham : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Coventry : Coventry and Warwickshire NHS partnership Trust
Strategic Timing of Antiretroviral Treatment
Crumpsall, Manchester : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Darlington : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Edinburgh : 1220.19.4407 Boehringer Ingelheim Investigational Site
Phase III Trial of BI 201335 in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)- Human Immunodeficiency Virus (HIV) Coinfected Patients
Edinburgh : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Gloucester : Gloucestershire Royal Hospital
Strategic Timing of Antiretroviral Treatment
Leicester : Leicester Royal Infirmary
Strategic Timing of Antiretroviral Treatment
London :
A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment
London : Homerton University Hospital
Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment
London : St Stephen's AIDS Trust
Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment
London : Barts & the London NHS Trust
Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment
London : St Mary's Hospital, London
Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.
London : St. George's Hospital, London
Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.
London : C&W Hospital, London
Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.
London : Homerton University Hospital
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
London : 1220.19.4408 Boehringer Ingelheim Investigational Site
Phase III Trial of BI 201335 in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)- Human Immunodeficiency Virus (HIV) Coinfected Patients
London : 1220.19.4402 Boehringer Ingelheim Investigational Site
Phase III Trial of BI 201335 in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)- Human Immunodeficiency Virus (HIV) Coinfected Patients
London : 1220.19.4401 Boehringer Ingelheim Investigational Site
Phase III Trial of BI 201335 in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)- Human Immunodeficiency Virus (HIV) Coinfected Patients
London : 1220.19.4403 Boehringer Ingelheim Investigational Site
Phase III Trial of BI 201335 in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)- Human Immunodeficiency Virus (HIV) Coinfected Patients
London : 1220.19.4404 Boehringer Ingelheim Investigational Site
Phase III Trial of BI 201335 in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)- Human Immunodeficiency Virus (HIV) Coinfected Patients
London : Collaborative HIV Paediatric Study
Post-marketing Safety Surveillance Program in Human Immunodeficiency Virus (HIV)-Infected Children Exposed to Atazanavir in Europe
London : European Collaborative Study
Post-marketing Safety Surveillance Program in Human Immunodeficiency Virus (HIV)-Infected Children Exposed to Atazanavir in Europe
London : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
London : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
London : Chelsea and Westminster Hospital
Strategic Timing of Antiretroviral Treatment
London : Royal Free Hospital
Strategic Timing of Antiretroviral Treatment
London : University College London Medical School
Strategic Timing of Antiretroviral Treatment
London : St. George's Healthcare NHS Trust
Strategic Timing of Antiretroviral Treatment
London : Imperial College Healthcare NHS Trust
Strategic Timing of Antiretroviral Treatment
London : Barts and the London NHS Trust
Strategic Timing of Antiretroviral Treatment
London : South London Healthcare NHS Trust
Strategic Timing of Antiretroviral Treatment
London : St. Thomas' Hospital
Strategic Timing of Antiretroviral Treatment
London : St. Mary's Hospital
The CogNaive Study: Assessing Changes in Neurocognitive Function in Treatment Naïve HIV-1 Positive Subjects
Manchester : North Manchester General Hospital
Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment
Manchester : 1220.19.4405 Boehringer Ingelheim Investigational Site
Phase III Trial of BI 201335 in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)- Human Immunodeficiency Virus (HIV) Coinfected Patients
Manchester : North Manchester General Hospital
Strategic Timing of Antiretroviral Treatment
Middlesbrough : The James Cook University Hospital
Strategic Timing of Antiretroviral Treatment
Newcastle upon Tyne : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Reading : Royal Berkshire Hospital
Strategic Timing of Antiretroviral Treatment
Sally Oak : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Sheffield : Sheffield Teaching Hospital NHS Foundation Trust
Strategic Timing of Antiretroviral Treatment
Shoreham, West Sussex : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Stoke on Trent, Staffordshire : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
United States
Washington : GSK Investigational Site
A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
Washington : Howard University Washington, DC NICHD CRS (5044) Updated
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Washington : Washington Hospital Center NICHD CRS (5023) Updated
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines
Washington : Georgetown University CRS (GU CRS) (1008)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
Washington : Medical Faculty Associates
Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment
View More »
Washington : Whitman Walker Clinic
Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment
Washington : Whitman-Walker Clinic
Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus
Washington : Whitman Walker Health
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
Washington : Georgetown University
Omega-3 Fatty Acids for High Triglycerides in HIV-infected Patients
Washington : Capital Medical Associates, PC
Open-Label Pilot Study to Evaluate Switching From a Regimen Consisting of Raltegravir Plus Emtricitabine/Tenofovir DF Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients
Washington : Dupont Circle Physician's Group
Open-Label Pilot Study to Evaluate Switching From a Regimen Consisting of Raltegravir Plus Emtricitabine/Tenofovir DF Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients
Washington : Capital Medical Associates, P.C.
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Washington : Dupont Circle Physicians Group, P.C.
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Washington : Dupont Circle Physician's Group
Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
Washington : 1220.19.0005 Boehringer Ingelheim Investigational Site
Phase III Trial of BI 201335 in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)- Human Immunodeficiency Virus (HIV) Coinfected Patients
Washington : Children'S National Medical Center
Phase IIIB Pediatric ATV Powder for Oral Use (POU) (PRINCE2)
Washington : Pfizer Investigational Site
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Washington : Capital Medical Associates, PC
Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults
Washington : Dupont Circle Physician's Group
Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults
Washington : Whitman-Walker Health
Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults
Washington : Whitman-Walker Clinic
SHARE: Simple HAART With Abacavir, Reyataz, and Epivir
Washington : George Washington University Medical Center
Strategic Timing of Antiretroviral Treatment
Washington : Georgetown University Medical Center
Strategic Timing of Antiretroviral Treatment
Washington : VA Medical Center
Strategic Timing of Antiretroviral Treatment
Washington : GSK Investigational Site
Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and/or Elivitegravir
Washington : Capital Medical Associates, PC
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Washington : Dupont Circle Physicians Group, P.C
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Zimbabwe
Chitungwiza : Seke North CRS
Study of Effects of Tenofovir on Bone Health and Kidneys During Pregnancy and Breastfeeding
Chitungwiza : St Mary's CRS
Study of Effects of Tenofovir on Bone Health and Kidneys During Pregnancy and Breastfeeding
Harare : UZ-Parirenyatwa CRS
Study of Effects of Tenofovir on Bone Health and Kidneys During Pregnancy and Breastfeeding
